Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2017 | Jan. 31, 2018 | Jun. 30, 2017 | |
Document and Entity Information | |||
Entity Registrant Name | ABBOTT LABORATORIES | ||
Entity Central Index Key | 1,800 | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2017 | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Public Float | $ 82,269,220,045 | ||
Entity Common Stock, Shares Outstanding | 1,746,333,892 | ||
Document Fiscal Year Focus | 2,017 | ||
Document Fiscal Period Focus | FY |
Consolidated Statement of Earni
Consolidated Statement of Earnings - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Consolidated Statement of Earnings | |||
Net Sales | $ 27,390 | $ 20,853 | $ 20,405 |
Cost of products sold, excluding amortization of intangible assets | 12,337 | 9,024 | 8,747 |
Amortization of intangible assets | 1,975 | 550 | 601 |
Research and development | 2,235 | 1,422 | 1,405 |
Selling, general and administrative | 9,117 | 6,672 | 6,785 |
Total Operating Cost and Expenses | 25,664 | 17,668 | 17,538 |
Operating Earnings | 1,726 | 3,185 | 2,867 |
Interest expense | 904 | 431 | 163 |
Interest income | (124) | (99) | (105) |
Net foreign exchange (gain) loss | (34) | 495 | (93) |
Other (income) expense, net | (1,251) | 945 | (281) |
Earnings from Continuing Operations Before Taxes | 2,231 | 1,413 | 3,183 |
Taxes on Earnings from Continuing Operations | 1,878 | 350 | 577 |
Earnings from Continuing Operations | 353 | 1,063 | 2,606 |
Earnings from Discontinued Operations, net of taxes | 124 | 321 | 65 |
Gain on sale of Discontinued Operations, net of taxes | 16 | 1,752 | |
Net Earnings from Discontinued Operations, net of taxes | 124 | 337 | 1,817 |
Net Earnings | $ 477 | $ 1,400 | $ 4,423 |
Basic Earnings Per Common Share -- | |||
Continuing Operations (in dollars per share) | $ 0.20 | $ 0.71 | $ 1.73 |
Discontinued Operations (in dollars per share) | 0.07 | 0.23 | 1.21 |
Net Earnings (in dollars per share) | 0.27 | 0.94 | 2.94 |
Diluted Earnings Per Common Share -- | |||
Continuing Operations (in dollars per share) | 0.20 | 0.71 | 1.72 |
Discontinued Operations (in dollars per share) | 0.07 | 0.23 | 1.20 |
Net Earnings (in dollars per share) | $ 0.27 | $ 0.94 | $ 2.92 |
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,740 | 1,477 | 1,496 |
Dilutive Common Stock Options (in shares) | 9 | 6 | 10 |
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,749 | 1,483 | 1,506 |
Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 5 | 1 |
Consolidated Statement of Compr
Consolidated Statement of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Consolidated Statement of Comprehensive Income | |||||
Net Earnings | $ (828) | $ 798 | $ 477 | $ 1,400 | $ 4,423 |
Foreign currency translation gain (loss) adjustments | 1,365 | (130) | (2,013) | ||
Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(61) in 2017, $(125) in 2016 and $101 in 2015 | (243) | (326) | 252 | ||
Unrealized gains (losses) on marketable equity securities, net of taxes of $(76) in 2017, $(28) in 2016 and $104 in 2015 | 64 | (134) | 64 | ||
Net (losses) gains on derivative instruments designated as cash flow hedges, net of taxes of $(43) in 2017, $(4) in 2016 and $(9) in 2015 | (134) | (15) | (35) | ||
Other Comprehensive Income (Loss) | 1,052 | (605) | (1,732) | ||
Comprehensive Income | 1,529 | 795 | 2,691 | ||
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||||
Cumulative foreign currency translation (loss) adjustments | (3,452) | (4,959) | (3,452) | (4,959) | (4,829) |
Net actuarial (losses) and prior service (cost) and credits | (2,521) | (2,284) | (2,521) | (2,284) | (1,958) |
Cumulative unrealized (losses) gains on marketable equity securities | (5) | (69) | (5) | (69) | 65 |
Cumulative (losses) gains on derivative instruments designated as cash flow hedges | (84) | 49 | (84) | 49 | 64 |
Accumulated other comprehensive income (loss) | $ (6,062) | $ (7,263) | $ (6,062) | $ (7,263) | $ (6,658) |
Consolidated Statement of Comp4
Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Consolidated Statement of Comprehensive Income | |||
Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, taxes | $ (61) | $ (125) | $ 101 |
Unrealized gains (losses) on marketable equity securities, taxes | (76) | (28) | 104 |
Net (losses) gains on derivative instruments designated as cash flow hedges, taxes | $ (43) | $ (4) | $ (9) |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Cash Flow From (Used in) Operating Activities: | |||
Net earnings | $ 477 | $ 1,400 | $ 4,423 |
Adjustments to reconcile earnings to net cash from operating activities - | |||
Depreciation | 1,046 | 803 | 871 |
Amortization of intangible assets | 1,975 | 550 | 601 |
Share-based compensation | 406 | 310 | 292 |
Impact of currency devaluation | 480 | ||
Amortization of inventory step-up | 907 | ||
Investing and financing (gains) losses, net | 47 | 86 | (18) |
Amortization of bridge financing fees | 5 | 165 | |
Gains on sale of businesses | (1,163) | (25) | (2,840) |
Mylan N.V. equity investment adjustment | 947 | ||
Gain on sale of Mylan N.V. shares | (45) | (207) | |
Trade receivables | (207) | (177) | (171) |
Inventories | 249 | (98) | (257) |
Prepaid expenses and other assets | 109 | 113 | 57 |
Trade accounts payable and other liabilities | 615 | (652) | (742) |
Income taxes | 1,149 | (699) | 957 |
Net Cash From Operating Activities | 5,570 | 3,203 | 2,966 |
Cash Flow From (Used in) Investing Activities: | |||
Acquisitions of property and equipment | (1,135) | (1,121) | (1,110) |
Acquisitions of businesses and technologies, net of cash acquired | (17,183) | (80) | (235) |
Proceeds from business dispositions | 6,042 | 25 | 230 |
Proceeds from the sale of Mylan N.V. shares | 2,704 | 2,290 | |
Purchases of investment securities | (210) | (2,823) | (4,933) |
Proceeds from sales of investment securities | 129 | 3,709 | 4,112 |
Other | 35 | 42 | 52 |
Net Cash From (Used in) Investing Activities | (9,618) | (248) | 406 |
Cash Flow From (Used in) Financing Activities: | |||
Proceeds from issuance of (repayments of) short-term debt and other | (1,034) | (1,767) | (1,281) |
Proceeds from issuance of long-term debt and debt with maturities over 3 months | 6,742 | 14,934 | 2,485 |
Repayments of long-term debt and debt with maturities over 3 months | (8,650) | (12) | (57) |
Payment of bridge financing fees | (170) | ||
Purchase of Alere preferred stock | (710) | ||
Acquisition and contingent consideration payments related to business acquisitions | (13) | (25) | (17) |
Purchases of common shares | (117) | (522) | (2,237) |
Proceeds from stock options exercised | 350 | 248 | 314 |
Dividends paid | (1,849) | (1,539) | (1,443) |
Net Cash From (Used in) Financing Activities | (5,281) | 11,147 | (2,236) |
Effect of exchange rate changes on cash and cash equivalents | 116 | (483) | (198) |
Net (Decrease) Increase in Cash and Cash Equivalents | (9,213) | 13,619 | 938 |
Cash and Cash Equivalents, Beginning of Year | 18,620 | 5,001 | 4,063 |
Cash and Cash Equivalents, End of Year | 9,407 | 18,620 | 5,001 |
Supplemental Cash Flow Information: | |||
Income taxes paid | 570 | 620 | 631 |
Interest paid | $ 917 | $ 181 | $ 166 |
Consolidated Balance Sheet
Consolidated Balance Sheet - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 |
Current Assets: | ||
Cash and cash equivalents | $ 9,407 | $ 18,620 |
Investments, primarily bank time deposits and U.S. treasury bills | 203 | 155 |
Trade receivables, less allowances of - 2017: $294; 2016: $250 | 5,249 | 3,248 |
Inventories: | ||
Finished products | 2,339 | 1,624 |
Work in process | 472 | 294 |
Materials | 790 | 516 |
Total inventories | 3,601 | 2,434 |
Other prepaid expenses and receivables | 1,667 | 1,806 |
Current assets held for disposition | 20 | 513 |
Total Current Assets | 20,147 | 26,776 |
Investments | 883 | 2,947 |
Property and Equipment, at Cost: | ||
Land | 526 | 408 |
Buildings | 3,613 | 2,602 |
Equipment | 10,394 | 8,394 |
Construction in progress | 732 | 962 |
Property and Equipment, at cost | 15,265 | 12,366 |
Less: accumulated depreciation and amortization | 7,658 | 6,661 |
Net Property and Equipment | 7,607 | 5,705 |
Intangible Assets, net of amortization | 21,473 | 4,539 |
Goodwill | 24,020 | 7,683 |
Deferred Income Taxes and Other Assets | 1,944 | 2,263 |
Non-current Assets Held for Disposition | 176 | 2,753 |
Total Assets | 76,250 | 52,666 |
Current Liabilities: | ||
Short-term borrowings | 206 | 1,322 |
Trade accounts payable | 2,402 | 1,178 |
Salaries, wages and commissions | 1,187 | 752 |
Other accrued liabilities | 3,811 | 2,581 |
Dividends payable | 489 | 391 |
Income taxes payable | 309 | 188 |
Current portion of long-term debt | 508 | 3 |
Current liabilities held for disposition | 245 | |
Total Current Liabilities | 8,912 | 6,660 |
Long-term debt | 27,210 | 20,681 |
Post-employment obligations and other long-term liabilities | 9,030 | 4,549 |
Non-current liabilities held for disposition | 59 | |
Commitments and Contingencies | ||
Shareholders' Investment: | ||
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2017: 1,965,908,188; 2016: 1,707,475,455 | 23,206 | 13,027 |
Common shares held in treasury, at cost - Shares: 2017: 222,305,719; 2016: 234,606,250 | (10,225) | (10,791) |
Earnings employed in the business | 23,978 | 25,565 |
Accumulated other comprehensive income (loss) | (6,062) | (7,263) |
Total Abbott Shareholders' Investment | 30,897 | 20,538 |
Noncontrolling Interests in Subsidiaries | 201 | 179 |
Total Shareholders' Investment | 31,098 | 20,717 |
Total Liabilities and Shareholders' Investment | $ 76,250 | $ 52,666 |
Consolidated Balance Sheet (Par
Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 |
Consolidated Balance Sheet | ||
Trade receivables, allowances (in dollars) | $ 294 | $ 250 |
Preferred shares, par value (in dollars per share) | $ 1 | $ 1 |
Preferred shares, Authorized shares | 1,000,000 | 1,000,000 |
Preferred shares, issued shares | 0 | 0 |
Common shares, Authorized shares | 2,400,000,000 | 2,400,000,000 |
Common shares, Issued shares | 1,965,908,188 | 1,707,475,455 |
Common shares held in treasury, shares | 222,305,719 | 234,606,250 |
Consolidated Statement of Share
Consolidated Statement of Shareholders' Investment - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||
Dec. 31, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Increase (Decrease) in Shareholders' Investment | |||||||
Beginning of Year | $ 20,717 | $ 20,717 | |||||
Net Earnings | $ (828) | 419 | $ 798 | $ 316 | 477 | $ 1,400 | $ 4,423 |
Other comprehensive income (loss) | 1,052 | (605) | (1,732) | ||||
End of Year | 31,098 | 20,717 | 31,098 | 20,717 | |||
Common Shares: | |||||||
Increase (Decrease) in Shareholders' Investment | |||||||
Beginning of Year | 13,027 | 12,734 | 13,027 | 12,734 | 12,383 | ||
Issued under incentive stock programs | 242 | 222 | 289 | ||||
Issued for St. Jude Medical acquisition | 9,835 | ||||||
Share-based compensation | 406 | 311 | 292 | ||||
Issuance of restricted stock awards | (304) | (240) | (230) | ||||
End of Year | 23,206 | 13,027 | 23,206 | 13,027 | 12,734 | ||
Common Shares Held in Treasury: | |||||||
Increase (Decrease) in Shareholders' Investment | |||||||
Beginning of Year | (10,791) | (10,622) | (10,791) | (10,622) | (8,678) | ||
Issued under incentive stock programs | 400 | 250 | 250 | ||||
Issued for St. Jude Medical acquisition | 180 | ||||||
Purchased | (14) | (419) | (2,194) | ||||
End of Year | (10,225) | (10,791) | (10,225) | (10,791) | (10,622) | ||
Earnings Employed in the Business: | |||||||
Increase (Decrease) in Shareholders' Investment | |||||||
Beginning of Year | 25,565 | 25,757 | 25,565 | 25,757 | 22,874 | ||
Net Earnings | 477 | 1,400 | 4,423 | ||||
Cash dividends declared on common shares (per share - 2017: $1.075; 2016: $1.045; 2015: $0.98) | (1,947) | (1,547) | (1,464) | ||||
Effect of common and treasury share transactions | (117) | (45) | (76) | ||||
End of Year | 23,978 | 25,565 | 23,978 | 25,565 | 25,757 | ||
Accumulated Other Comprehensive Income (Loss): | |||||||
Increase (Decrease) in Shareholders' Investment | |||||||
Beginning of Year | (7,263) | (6,658) | (7,263) | (6,658) | (5,053) | ||
Business dispositions / separation | 149 | 127 | |||||
Other comprehensive income (loss) | 1,052 | (605) | (1,732) | ||||
End of Year | (6,062) | (7,263) | (6,062) | (7,263) | (6,658) | ||
Noncontrolling Interests in Subsidiaries: | |||||||
Increase (Decrease) in Shareholders' Investment | |||||||
Beginning of Year | $ 179 | $ 115 | 179 | 115 | 113 | ||
Noncontrolling Interests' share of income, business combinations, net of distributions and share repurchases | 22 | 64 | 2 | ||||
End of Year | $ 201 | $ 179 | $ 201 | $ 179 | $ 115 |
Consolidated Statement of Shar9
Consolidated Statement of Shareholders' Investment (Parenthetical) - $ / shares | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Common Shares: | |||
Increase (Decrease) in Shareholders' Investment | |||
Beginning of Year (in shares) | 1,707,475,455 | 1,702,017,390 | 1,694,929,949 |
Issued under incentive stock programs (in shares) | 8,834,924 | 5,458,065 | 7,087,441 |
Issued for St. Jude Medical acquisition (in shares) | 249,597,809 | ||
End of Year (in shares) | 1,965,908,188 | 1,707,475,455 | 1,702,017,390 |
Common Shares Held in Treasury: | |||
Increase (Decrease) in Shareholders' Investment | |||
Beginning of Year (in shares) | 234,606,250 | 229,352,338 | 186,894,515 |
Issued under incentive stock programs (in shares) | 8,696,320 | 5,398,469 | 5,381,586 |
Issued for St. Jude Medical acquisition (in shares) | 3,906,848 | ||
Purchased (in shares) | 302,637 | 10,652,381 | 47,839,409 |
End of Year (in shares) | 222,305,719 | 234,606,250 | 229,352,338 |
Earnings Employed in the Business: | |||
Increase (Decrease) in Shareholders' Investment | |||
Cash dividends declared on common shares (in dollars per share) | $ 1.075 | $ 1.045 | $ 0.98 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2017 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | Note 1 — Summary of Significant Accounting Policies NATURE OF BUSINESS — Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. CHANGES IN PRESENTATION — In September 2016, Abbott announced that it had entered into an agreement to sell Abbott Medical Optics (AMO), its vision care business, to Johnson & Johnson. The transaction closed in February 2017. The operating results of AMO up to the date of sale were reported as part of continuing operations as AMO did not qualify for reporting as a discontinued operation. The assets and liabilities of AMO are reported as held for disposition in Abbott's Consolidated Balance Sheet at December 31, 2016. On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for equity ownership of a newly formed entity that combined Mylan's existing business and Abbott's developed markets pharmaceuticals business. On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. The historical operating results of these two businesses up to the date of sale are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations, net of taxes line in Abbott's Consolidated Statement of Earnings. The cash flows of these businesses are included in Abbott's Consolidated Statement of Cash Flows up to the date of disposition. See Note 2 — Discontinued Operations for additional information. BASIS OF CONSOLIDATION — The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. USE OF ESTIMATES — The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for sales rebates; income taxes; pension and other post-employment benefits, including certain asset values that are based on significant unobservable inputs; valuation of intangible assets; litigation; derivative financial instruments; and inventory and accounts receivable exposures. FOREIGN CURRENCY TRANSLATION — The statements of earnings of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in equity as a component of Accumulated other comprehensive income (loss). Transaction gains and losses are recorded on the Net foreign exchange (gain) loss line of the Consolidated Statement of Earnings. REVENUE RECOGNITION — Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Sales incentives to customers are not material. Historical data is readily available and reliable, and is used for estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer's normal requirements are recorded when the conditions noted above are met. In those situations, management records a returns reserve for such revenue, if necessary. In certain of Abbott's businesses, primarily within diagnostics and medical optics, prior to its divestiture, Abbott participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements). Under these arrangements, Abbott recognizes revenue upon delivery of the product or performance of the service and allocates the revenue based on the relative selling price of each deliverable, which is based primarily on vendor specific objective evidence. Sales of product rights for marketable products are recorded as revenue upon disposition of the rights. Revenue from license of product rights, or for performance of research or selling activities, is recorded over the periods earned. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers , which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for Abbott in the first quarter of 2018. Abbott's revenues are primarily comprised of product sales. Abbott completed a thorough evaluation of the new standard including a detailed review of Abbott's revenue streams and contracts. Abbott does not expect the adoption of the new standard to have a material impact on its consolidated financial statements. Abbott will use the modified retrospective method to adopt this standard. INCOME TAXES — Deferred income taxes are provided for the tax effect of differences between the tax bases of assets and liabilities and their reported amounts in the financial statements at the enacted statutory rate to be in effect when the taxes are paid. No additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax related to the U.S. Tax Cuts and Jobs Act, or any additional outside basis differences that exist, as these amounts continue to be indefinitely reinvested in foreign operations. Interest and penalties on income tax obligations are included in taxes on income. EARNINGS PER SHARE — Unvested restricted stock units and awards that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares in 2017, 2016 and 2015 were $346 million, $1.057 billion and $2.595 billion, respectively. Net earnings allocated to common shares in 2017, 2016 and 2015 were $468 million, $1.393 billion and $4.403 billion, respectively. PENSION AND POST-EMPLOYMENT BENEFITS — Abbott accrues for the actuarially determined cost of pension and post-employment benefits over the service attribution periods of the employees. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on plan assets. Differences between the expected long-term return on plan assets and the actual return are amortized over a five-year period. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method. FAIR VALUE MEASUREMENTS — For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model. Purchased intangible assets are recorded at fair value. The fair value of significant purchased intangible assets is based on independent appraisals. Abbott uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Intangible assets are reviewed for impairment on a quarterly basis. Goodwill and indefinite-lived intangible assets are tested for impairment at least annually. SHARE-BASED COMPENSATION — The fair value of stock options and restricted stock awards and units are amortized over their requisite service period, which could be shorter than the vesting period if an employee is retirement eligible, with a charge to compensation expense. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . ASU 2016-09 modifies several aspects of the accounting for share-based payment transactions, including the accounting for income taxes and classification on the statement of cash flows. Abbott adopted the standard in the first quarter of 2017 and the following changes were made to the presentation of Abbott's financial statements: • All excess tax benefits or tax deficiencies are now recognized as income tax benefit or expense as applicable. Previously, Abbott recorded the benefits to Shareholders' Investment. The tax benefit recorded in Abbott's Consolidated Statement of Earnings for 2017 was $120 million. The standard does not permit retrospective presentation of this benefit in prior years. • The tax benefit or deficiency is required to be classified as an operating activity in the statement of cash flows. Previously, it was required to be classified within financing activities. Abbott has adopted this standard on a prospective basis and has not revised the classification of the excess tax benefit in the prior year's Consolidated Statement of Cash Flows. LITIGATION — Abbott accounts for litigation losses in accordance with FASB ASC No. 450, "Contingencies." Under ASC No. 450, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. Legal fees are recorded as incurred. CASH, CASH EQUIVALENTS AND INVESTMENTS — Cash equivalents consist of bank time deposits, U.S. government securities money market funds and U.S. treasury bills with original maturities of three months or less. Abbott holds certain investments with a carrying value of approximately $235 million that are accounted for under the equity method of accounting. Investments held in a rabbi trust are accounted for as trading securities. All other investments in marketable equity securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in Accumulated other comprehensive income (loss). Investments in equity securities that are not traded on public stock exchanges are recorded at cost. Investments in debt securities are classified as held-to-maturity, as management has both the intent and ability to hold these securities to maturity, and are reported at cost, net of any unamortized premium or discount. Income relating to these securities is reported as interest income. Abbott reviews the carrying value of investments each quarter to determine whether an other than temporary decline in fair value exists. Abbott considers factors affecting the investee, factors affecting the industry the investee operates in and general equity market trends. Abbott considers the length of time an investment's fair value has been below carrying value and the near-term prospects for recovery to carrying value. When Abbott determines that an other than temporary decline has occurred, the investment is written down with a charge to Other (income) expense, net. TRADE RECEIVABLE VALUATIONS — Accounts receivable are stated at their net realizable value. The allowance against gross trade receivables reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are charged off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. INVENTORIES — Inventories are stated at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. PROPERTY AND EQUIPMENT — Depreciation and amortization are provided on a straight-line basis over the estimated useful lives of the assets. The following table shows estimated useful lives of property and equipment: Classification Estimated Useful Lives Buildings 10 to 50 years (average 27 years) Equipment 3 to 20 years (average 11 years) PRODUCT LIABILITY — Abbott accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The liabilities are adjusted quarterly as additional information becomes available. Receivables for insurance recoveries for product liability claims are recorded as assets, on an undiscounted basis, when it is probable that a recovery will be realized. Product liability losses are self-insured. RESEARCH AND DEVELOPMENT COSTS — Internal research and development costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are achieved. ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) — The initial costs of rights to IPR&D projects obtained in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until completed and are then amortized over the remaining useful life. Collaborations are not significant. CONCENTRATION OF RISK AND GUARANTEES — Due to the nature of its operations, Abbott is not subject to significant concentration risks relating to customers, products or geographic locations. Product warranties are not significant. Abbott has no material exposures to off-balance sheet arrangements; no special purpose entities; nor activities that include non-exchange-traded contracts accounted for at fair value. Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies, which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events. |
Discontinued Operations
Discontinued Operations | 12 Months Ended |
Dec. 31, 2017 | |
Discontinued Operations | |
Discontinued Operations | Note 2 — Discontinued Operations On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for 110 million ordinary shares (or approximately 22%) of a newly formed entity (Mylan N.V.) that combined Mylan's existing business and Abbott's developed markets branded generics pharmaceuticals business. Mylan N.V. is publicly traded. Historically, this business was included in Abbott's Established Pharmaceutical Products segment. Abbott retained its branded generics pharmaceuticals business in emerging markets. At the date of closing, the 110 million Mylan N.V. ordinary shares that Abbott received were valued at $5.77 billion and Abbott recorded an after-tax gain on the sale of the business of approximately $1.6 billion. The shareholder agreement with Mylan N.V. includes voting and other restrictions that prevent Abbott from exercising significant influence over the operating and financial policies of Mylan N.V. At the close of this transaction Abbott and Mylan entered into a transition services agreement pursuant to which Abbott and Mylan provided various back office support services to each other on an interim transitional basis for up to 2 years. Certain services were extended for an additional five to ten months. Charges by Abbott under this transition services agreement were recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Consolidated Statement of Earnings. This transition support did not constitute significant continuing involvement in Mylan's operations. Abbott also entered into manufacturing supply agreements with Mylan related to certain products, with the supply term ranging from 3 to 10 years and requiring a 2 year notice prior to termination. The cash flows associated with these transition services and manufacturing supply agreements are not expected to be significant, and therefore, these cash flows are not direct cash flows of the disposed component under Accounting Standards Codification 205. In April 2015, Abbott sold 40.25 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. Abbott recorded a pretax gain of $207 million on $2.29 billion in net proceeds from the sale of these shares. The gain is recognized in the Other (income) expense line of the 2015 Consolidated Statement of Earnings. As a result of this sale, Abbott's ownership interest in Mylan N.V. decreased to approximately 14%. In 2017, Abbott sold 69.75 million ordinary shares of Mylan N.V. and received $2.704 billion in proceeds. Abbott recorded a $45 million gain from the sale of these ordinary shares in 2017, which was recognized in the Other (income) expense, net line of the Consolidated Statement of Earnings. Abbott no longer has an ownership interest in Mylan N.V. On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. Abbott received cash proceeds of $230 million and reported an after tax gain on the sale of approximately $130 million. In the first quarter of 2016, Abbott received an additional $25 million of proceeds due to the expiration of a holdback agreement associated with the sale of this business and reported an after-tax gain of $16 million. As a result of the disposition of the above businesses, the operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from Discontinued Operations, net of taxes line in the Consolidated Statement of Earnings. Discontinued operations include an allocation of interest expense assuming a uniform ratio of consolidated debt to equity for all of Abbott's historical operations. On January 1, 2013, Abbott completed the separation of AbbVie Inc. (AbbVie), which was formed to hold Abbott's research-based proprietary pharmaceuticals business. Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business. AbbVie generally will be liable for all other taxes attributable to its business. The operating results of Abbott's developed markets branded generics pharmaceuticals and animal health businesses, as well as the income tax benefit related to the businesses transferred to AbbVie, which are being reported as discontinued operations are as follows: Year Ended (in millions) 2017 2016 2015 Net Sales Developed markets generics pharmaceuticals and animal health businesses $ — $ — $ AbbVie — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ — $ — $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings (Loss) Before Tax Developed markets generics pharmaceuticals and animal health businesses $ $ ) $ AbbVie — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ) $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Earnings Developed markets generics pharmaceuticals and animal health businesses $ $ $ AbbVie ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The net earnings of discontinued operations include income tax benefits of $109 million in 2017, $325 million in 2016 and $52 million in 2015. The tax benefits in 2017 and 2016 primarily relate to the resolution of various tax positions related to AbbVie's operations for years prior to the separation. 2015 includes $48 million of tax benefits related to the resolution of various tax positions related to prior years. The sale of the developed markets branded generics pharmaceuticals and animal health business in 2015 resulted in the recognition of a pretax gain of $2.840 billion, tax expense of $1.088 billion and an after tax gain of $1.752 billion. The 2015 tax provision included $667 million of tax expense on certain prior year income earned outside the U.S. related to the developed markets branded generics pharmaceuticals businesses that were not designated as permanently reinvested overseas. |
Assets and Liabilities Held for
Assets and Liabilities Held for Disposition | 12 Months Ended |
Dec. 31, 2017 | |
Assets and Liabilities Held for Disposition | |
Assets and Liabilities Held for Disposition | Note 3 — Assets and Liabilities Held for Disposition In September 2016, Abbott announced that it entered into a definitive agreement to sell Abbott Medical Optics (AMO), its vision care business, to Johnson & Johnson for $4.325 billion in cash, subject to customary purchase price adjustments for cash, debt and working capital. The decision to sell AMO reflected Abbott's proactive shaping of its portfolio in line with its strategic priorities. In February 2017, Abbott completed the sale of AMO to Johnson & Johnson and recognized a pre-tax gain of $1.163 billion including working capital adjustments, which was reported in the Other (income) expense, net line of the Consolidated Statement of Earnings in 2017. Abbott recorded an after-tax gain of $728 million in 2017 related to the sale of AMO. The operating results of AMO up to the date of sale continued to be included in Earnings from continuing operations as the business did not qualify for reporting as discontinued operations. For 2017, 2016 and 2015, the AMO earnings (losses) before taxes included in Abbott's consolidated earnings were $(18) million, $30 million and $64 million, respectively. Assets and liabilities of AMO were classified as held for disposition in Abbott's Consolidated Balance Sheet as of December 31, 2016. As discussed in Note 6 — Business Acquisitions, in conjunction with the acquisition of Alere Inc. (Alere), Abbott sold the Triage MeterPro cardiovascular and toxicology business and the assets and liabilities related to its B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers to Quidel Corporation (Quidel). The legal transfer of certain assets and liabilities related to these businesses did not occur at the close of the sale to Quidel due to, among other factors, the time required to transfer marketing authorizations and other regulatory requirements in various countries. Under the terms of the sale agreement with Abbott, Quidel is subject to the risks and entitled to the benefits generated by these operations and assets. The assets and liabilities presented as held for disposition in the Consolidated Balance Sheet as of December 31, 2017, primarily relate to the businesses sold to Quidel. The following is a summary of the assets and liabilities held for disposition as of December 31, 2017 and 2016: (in millions) December 31, December 31, Trade receivables, net $ $ Total inventories Prepaid expenses and other current assets — ​ ​ ​ ​ ​ ​ ​ ​ Current assets held for disposition ​ ​ ​ ​ ​ ​ ​ ​ Net property and equipment Intangible assets, net of amortization Goodwill Deferred income taxes and other assets — ​ ​ ​ ​ ​ ​ ​ ​ Non-current assets held for disposition ​ ​ ​ ​ ​ ​ ​ ​ Total assets held for disposition $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade accounts payable $ — $ Salaries, wages, commissions and other accrued liabilities — ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities held for disposition — Post-employment obligations, deferred income taxes and other long-term liabilities — ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities held for disposition $ — $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Supplemental Financial Informat
Supplemental Financial Information | 12 Months Ended |
Dec. 31, 2017 | |
Supplemental Financial Information | |
Supplemental Financial Information | Note 4 — Supplemental Financial Information Other (income) expense, net, for 2017 includes a pre-tax gain of $1.163 billion related to the sale of AMO to Jonhson & Johnson. See Note 3 — Assets and Liabilities Held for Disposition for further details. Other (income) expense, net, for 2016 includes expense of $947 million to adjust Abbott's holding of Mylan N.V. ordinary shares due to a decline in the fair value of the securities which was considered by Abbott to be other than temporary. Other (income) expense, net, for 2015 primarily relates to a $207 million gain on the sale of a portion of Abbott's position in Mylan N.V. stock and $79 million of income resulting from a decrease in the fair value of contingent consideration related to a business acquisition. The detail of various balance sheet components is as follows: 2017 2016 (in millions) Long-term Investments: Equity securities $ $ Other ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The decrease in long-term investments relates to the sale in 2017 of the remaining ordinary shares of Mylan N.V. that Abbott held. Abbott sold 69.75 million ordinary shares of Mylan N.V. and received $2.704 billion in proceeds. Abbott recorded a $45 million pre-tax gain in 2017 related to the sale of these ordinary shares, which was recognized in the Other (income) expense, net line of the Consolidated Statement of Earnings. As of December 31, 2017, Abbott no longer has an ownership interest in Mylan N.V. Abbott's equity securities as of December 31, 2017, include $363 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency. 2017 2016 (in millions) Other Accrued Liabilities: Accrued rebates payable to government agencies $ $ Accrued other rebates (a) All other ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) Accrued wholesaler chargeback rebates of $178 million and $214 million at December 31, 2017 and 2016, respectively, are netted in trade receivables because Abbott's customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products. 2017 2016 (in millions) Post-employment Obligations and Other Long-term Liabilities: Defined benefit pension plans and post-employment medical and dental plans for significant plans $ $ Deferred income taxes All other (b) ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (b) 2017 includes approximately $835 million of net unrecognized tax benefits, as well as approximately $100 million of acquisition consideration payable. 2016 includes approximately $560 million of net unrecognized tax benefits, as well as approximately $130 million of acquisition consideration payable. Since January 2010, Venezuela has been designated as a highly inflationary economy under U.S. GAAP. In 2014 and 2015, the government of Venezuela operated multiple mechanisms to exchange bolivars into U.S. dollars. These mechanisms included the CENCOEX, SICAD, and SIMADI rates, which stood at 6.3, 13.5, and approximately 200, respectively, at December 31, 2015. In 2015, Abbott continued to use the CENCOEX rate of 6.3 Venezuelan bolivars to the U.S. dollar to report the results, financial position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela. On February 17, 2016, the Venezuelan government announced that the three-tier exchange rate system would be reduced to two rates renamed the DIPRO and DICOM rates. The DIPRO rate is the official rate for food and medicine imports and was adjusted from 6.3 to 10 bolivars per U.S. dollar. The DICOM rate is a floating market rate published daily by the Venezuelan central bank, which at the end of the first quarter of 2016 was approximately 263 bolivars per U.S. dollar. As a result of decreasing government approvals to convert bolivars to U.S. dollars to pay for intercompany accounts, as well as the accelerating deterioration of economic conditions in the country, Abbott concluded that it was appropriate to move to the DICOM rate at the end of the first quarter of 2016. As a result, Abbott recorded a foreign currency exchange loss of $480 million in 2016 to revalue its net monetary assets in Venezuela. Abbott is continuing to use the DICOM rate to report the results of operations and to remeasure net monetary assets for Venezuela at the end of each quarter. As of December 31, 2017, Abbott's investment in its Venezuelan operations was not significant. As a result, any additional future foreign currency losses related to Venezuela would not be material. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) | 12 Months Ended |
Dec. 31, 2017 | |
Accumulated Other Comprehensive Income (Loss) | |
Accumulated Other Comprehensive Income (Loss) | Note 5 — Accumulated Other Comprehensive Income (Loss) The components of the changes in accumulated other comprehensive income (loss) from continuing operations, net of income taxes, are as follows: ( in millions ) Cumulative Net Cumulative Cumulative Total Balance at December 31, 2015 $ ) $ ) $ $ $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive income (loss) before reclassifications ) ) ) ) (Income) loss amounts reclassified from accumulated other comprehensive income (a) — ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net current period other comprehensive income (loss) ) ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2016 ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Impact of business dispositions — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive income (loss) before reclassifications ) ) (Income) loss amounts reclassified from accumulated other comprehensive income (a) — ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net current period other comprehensive income (loss) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2017 $ ) $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) Reclassified amounts for foreign currency translation adjustments are recorded in the Consolidated Statement of Earnings as Net Foreign exchange (gain) loss; gains (losses) on marketable equity securities are recorded as Other (income) expense and gains/losses related to cash flow hedges are recorded as Cost of product sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan cost — see Note 13 for additional information. |
Business Acquisitions
Business Acquisitions | 12 Months Ended |
Dec. 31, 2017 | |
Business Acquisitions | |
Business Acquisitions | Note 6 — Business Acquisitions On January 4, 2017, Abbott completed the acquisition of St. Jude Medical, a global medical device manufacturer, for approximately $23.6 billion, including approximately $13.6 billion in cash and approximately $10 billion in Abbott common shares, which represented approximately 254 million shares of Abbott common stock, based on Abbott's closing stock price on the acquisition date. As part of the acquisition, approximately $5.9 billion of St. Jude Medical's debt was assumed, repaid or refinanced by Abbott. The acquisition provides expanded opportunities for future growth and is an important part of the company's ongoing effort to develop a strong, diverse portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals. The combined business competes in nearly every area of the cardiovascular device market, as well as in the neuromodulation market. Under the terms of the agreement, for each St. Jude Medical common share, St. Jude Medical shareholders received $46.75 in cash and 0.8708 of an Abbott common share. At an Abbott stock price of $39.36, which reflects the closing price on January 4, 2017, this represented a value of approximately $81 per St. Jude Medical common share and total purchase consideration of $23.6 billion. The cash portion of the acquisition was funded through a combination of medium and long-term debt issued in November 2016 and a $2.0 billion 120-day senior unsecured bridge term loan facility which was subsequently repaid. The final allocation of the fair value of the St. Jude Medical acquisition is shown in the table below. (in billions) Acquired intangible assets, non-deductible $ Goodwill, non-deductible Acquired net tangible assets Deferred income taxes recorded at acquisition ) Net debt ) ​ ​ ​ ​ ​ Total final allocation of fair value $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The goodwill is primarily attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. The goodwill is identifiable to the Cardiovascular and Neuromodulation Products reportable segment. The acquired tangible assets consist primarily of trade accounts receivable of approximately $1.1 billion, inventory of approximately $1.7 billion, other current assets of $176 million, property and equipment of approximately $1.5 billion, and other long-term assets of approximately $455 million. The acquired tangible liabilities consist of trade accounts payable and other current liabilities of approximately $1.1 billion and other non-current liabilities of approximately $870 million. In 2016, Abbott and St. Jude Medical agreed to sell certain businesses to Terumo Corporation (Terumo) for approximately $1.12 billion. The sale included the St. Jude Medical Angio-Seal™ and Femoseal™ vascular closure and Abbott's Vado® Steerable Sheath businesses. The sale closed on January 20, 2017 and no gain or loss was recorded in the Consolidated Statement of Earnings. On October 3, 2017, Abbott acquired Alere Inc. (Alere), a diagnostic device and service provider, for $51.00 per common share in cash, which equated to a purchase price of approximately $4.5 billion. As part of the acquisition, Abbott tendered for Alere's preferred shares for a total value of approximately $0.7 billion. In addition, approximately $3.0 billion of Alere's debt was assumed and subsequently repaid. The acquisition establishes Abbott as a leader in point of care testing, expands Abbott's global diagnostics presence and provides access to new products, channels and geographies. Abbott utilized a combination of cash on hand and debt to fund the acquisition. See Note 10 — Debt and Lines of Credit for further details regarding the debt utilized for the acquisition. The preliminary allocation of the fair value of the Alere acquisition is shown in the table below. The allocation of the fair value of the acquisition will be finalized when the valuation is completed and differences between the preliminary and final allocation could be material. (in billions) Acquired intangible assets, non-deductible $ Goodwill, non-deductible Acquired net tangible assets Deferred income taxes recorded at acquisition ) Net debt ) Preferred stock ) ​ ​ ​ ​ ​ Total preliminary allocation of fair value $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The goodwill is primarily attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. The goodwill is identifiable to the Diagnostic Products reportable segment. The acquired tangible assets consist primarily of trade accounts receivable of approximately $430 million, inventory of approximately $425 million, other current assets of $206 million, property and equipment of approximately $540 million, and other long-term assets of $112 million. The acquired tangible liabilities consist of trade accounts payable and other current liabilities of approximately $625 million and other non-current liabilities of approximately $160 million. In the third quarter of 2017, Alere entered into agreements to sell its Triage MeterPro cardiovascular and toxicology business and the assets and liabilities related to its B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers to Quidel Corporation (Quidel). The transactions with Quidel reflect a total purchase price of $400 million payable at the close of the transaction, $240 million payable in six annual installments beginning approximately six months after the close of the transaction, and contingent consideration with a maximum value of $40 million. In the third quarter of 2017, Alere entered into an agreement with Siemens Diagnostics Holding II B.V. (Siemens) to sell its subsidiary, Epocal Inc., for approximately $200 million payable at the close of the transaction. Alere agreed to divest these businesses in connection with the review by the Federal Trade Commission and the European Commission of Abbott's agreement to acquire Alere. The sale to Quidel closed on October 6, 2017, and the sale to Siemens closed on October 31, 2017. No gain or loss on these sales was recorded in the Consolidated Statement of Earnings. In 2017, consolidated Abbott results include $6.5 billion of sales and a pre-tax loss of approximately $1.3 billion related to the St. Jude Medical and Alere acquisitions, including approximately $1.5 billion of intangible amortization and $907 million of inventory step-up amortization. The pre-tax loss excludes acquisition, integration and restructuring-related costs. If the acquisitions of St. Jude Medical and Alere had occurred at the beginning of 2016, unaudited pro forma consolidated net sales would have been approximately $28.9 billion and the unaudited pro forma consolidated net loss from continuing operations would have been approximately $485 million in 2016. This includes amortization of approximately $940 million of inventory step-up and $1.7 billion of intangibles related to St. Jude Medical and Alere. For 2017, unaudited pro forma consolidated net sales would have been approximately $28.9 billion and unaudited pro forma consolidated net earnings from continuing operations would have been approximately $750 million, which includes $225 million of intangible amortization related to Alere. The unaudited pro forma consolidated net earnings from continuing operations for 2017 exclude inventory step-up amortization related to St. Jude Medical and Alere of approximately $907 million which was recorded in 2017 but included in the 2016 unaudited pro forma results as noted above. The unaudited pro forma information is not necessarily indicative of the consolidated results of operations that would have been realized had the St. Jude Medical and Alere acquisitions been completed as of the beginning of 2016, nor is it meant to be indicative of future results of operations that the combined entity will experience. On July 17, 2017, Abbott commenced a tender offer to purchase for cash the 1.77 million outstanding shares of Alere's Series B Convertible Perpetual Preferred Stock at a price of $402 per share, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer. This tender offer was subject to the satisfaction of certain conditions, including Abbott's acquisition of Alere and upon there being validly tendered (and not properly withdrawn) at the expiration date of the tender offer that number of shares of Preferred Stock that equaled at least a majority of the Preferred Stock issued and outstanding at the expiration of the tender offer. The tender offer expired on October 3, 2017. All conditions to the offer were satisfied and Abbott accepted for payment the 1.748 million shares of Preferred Stock that were validly tendered (and not properly withdrawn). The remaining shares were cashed out for an amount equal to the $400.00 per share liquidation preference of such shares, plus accrued but unpaid dividends, without interest. Payment for all of the shares of Preferred Stock was made in the fourth quarter of 2017. In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately $225 million in cash plus additional payments up to $150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The final allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately $142 million, deferred tax assets and other net assets of approximately $18 million, deferred tax liabilities of approximately $85 million, and contingent consideration of approximately $70 million. The goodwill is identifiable to the Cardiovascular and Neuromodulation Products segment. If the acquisition of Tendyne had taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 12 Months Ended |
Dec. 31, 2017 | |
Goodwill and Intangible Assets | |
Goodwill and Intangible Assets | Note 7 — Goodwill and Intangible Assets The total amount of goodwill reported was $24.0 billion at December 31, 2017 and $7.7 billion at December 31, 2016. The amounts reported at December 31, 2017 and 2016 exclude goodwill reported in non-current assets held for disposition. In 2017, approximately $2.0 billion of goodwill was included as part of the net assets sold in the AMO divestiture. Goodwill increased by $17.2 billion in 2017 due to the completion of the St. Jude Medical and Alere acquisitions, partially offset by a decrease of $1.5 billion due to the sale of certain businesses to Terumo, Quidel and Siemens. Foreign currency translation increased goodwill by $653 million in 2017 and decreased goodwill by $66 million in 2016. Business acquisitions increased goodwill by approximately $79 million during 2016. The amount of goodwill related to reportable segments at December 31, 2017 was $3.2 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $4.1 billion for the Diagnostic Products segment, and $15.5 billion for the Cardiovascular and Neuromodulation Products segment. The Cardiovascular and Neuromodulation Products segment includes the amount previously reported under Abbott's Vascular Products segment, as well as the goodwill related to the St. Jude Medical acquisition. In 2017, there was no significant reduction of goodwill relating to impairments. The gross amount of amortizable intangible assets, primarily product rights and technology was $25.6 billion and $10.4 billion as of December 31, 2017 and 2016, respectively, and accumulated amortization was $8.1 billion and $6.2 billion as of December 31, 2017 and 2016, respectively. The December 31, 2016 amounts exclude net intangible assets reported in non-current assets held for disposition. As part of the sale of AMO in 2017, approximately $529 million of net intangible assets were included in the net assets sold. In 2017, the gross amount of amortizable intangible assets increased by approximately $14.5 billion due to the completion of the St. Jude Medical and Alere acquisitions, partially offset by a decrease of $210 million due to the sale of certain businesses to Quidel and Siemens. In 2016, intangible assets increased by approximately $104 million related to business acquisitions. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $3.9 billion and $349 million at December 31, 2017 and 2016, respectively. In 2017, in-process research and development increased by $4.5 billion due to the completion of the St. Jude Medical and Alere acquisitions, a portion of which became amortizable during the year. In 2017, Abbott also recorded a $53 million impairment of an in-process research and development project related to the Cardiovascular and Neuromodulation Products segment. In 2016, Abbott recorded an impairment of a $59 million in-process research and development project related to a non-reportable segment. Foreign currency translation increased intangible assets by $227 million in 2017 and $6 million in 2016. The estimated annual amortization expense for intangible assets recorded at December 31, 2017 is approximately $2.4 billion in 2018, $2.3 billion in 2019, $2.1 billion in 2020, $2.0 billion in 2021 and $2.0 billion in 2022. Amortizable intangible assets are amortized over 2 to 20 years (average 14 years). |
Restructuring Plans
Restructuring Plans | 12 Months Ended |
Dec. 31, 2017 | |
Restructuring Plans | |
Restructuring Plans | Note 8 — Restructuring Plans In 2017, Abbott management approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the cardiovascular and neuromodulation segment and Alere into the diagnostics segment, in order to leverage economies of scale and reduce costs. In 2017, charges of approximately $187 million, including one-time employee termination benefits were recorded, of which approximately $5 million is recorded in Cost of products sold and approximately $182 million in Selling, general and administrative expense. Abbott also assumed restructuring liabilities of approximately $23 million as part of the St. Jude Medical and Alere acquisitions. The following summarizes the activity in 2017 related to these actions and the status of the related accrual as of December 31, 2017: (in millions) Liabilities assumed as part of business acquisitions $ Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2017 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ From 2014 to 2017, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. Abbott recorded employee related severance and other charges of approximately $120 million in 2017, $33 million in 2016, and $95 million in 2015. Approximately $7 million in 2017, $9 million in 2016 and $18 million in 2015 are recorded in Cost of products sold, approximately $77 million in 2017, $5 million in 2016 and $34 million in 2015 are recorded in Research and development and approximately $36 million in 2017, $19 million in 2016 and $43 million in 2015 are recorded in Selling, general and administrative expense. Additional charges of approximately $2 million in 2017, $2 million in 2016 and $45 million in 2015 were recorded primarily for accelerated depreciation. The following summarizes the activity for these restructurings: (in millions) Restructuring charges recorded in 2014 $ Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2014 Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2015 Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2016 Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2017 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Incentive Stock Program
Incentive Stock Program | 12 Months Ended |
Dec. 31, 2017 | |
Incentive Stock Program | |
Incentive Stock Program | Note 9 — Incentive Stock Program In connection with the completion of the St. Jude Medical acquisition in the first quarter of 2017, unvested St. Jude Medical stock options and restricted stock units were assumed by Abbott and converted into Abbott options and restricted stock units (as applicable) of substantially equivalent value, in accordance with the merger agreement. The number of shares underlying the converted options was 7,364,571 at a weighted average exercise price of $30.50. The number of restricted stock units converted was 2,324,500 at a weighted average grant date fair value of $37.69. The 2017 Incentive Stock Program authorizes the granting of nonqualified stock options, restricted stock awards, restricted stock units, performance awards, foreign benefits and other share-based awards. Stock options and restricted stock awards and units comprise the majority of benefits that have been granted and are currently outstanding under this program and a prior program. In 2017, Abbott granted 4,985,970 stock options, 580,203 restricted stock awards and 7,687,009 restricted stock units under this program. Under Abbott's stock incentive programs, the purchase price of shares under option must be at least equal to the fair market value of the common stock on the date of grant, and the maximum term of an option is 10 years. Options generally vest equally over three years. Restricted stock awards generally vest between 3 and 5 years and for restricted stock awards that vest over 5 years, no more than one-third of the award vests in any one year upon Abbott reaching a minimum return on equity target. Restricted stock units vest over three years and upon vesting, the recipient receives one share of Abbott stock for each vested restricted stock unit. The aggregate fair market value of restricted stock awards and units is recognized as expense over the requisite service period, which may be shorter than the vesting period if an employee is retirement eligible. Forfeitures are estimated at the time of grant. Restricted stock awards and settlement of vested restricted stock units are issued out of treasury shares. Abbott generally issues new shares for exercises of stock options. As a policy, Abbott does not purchase its shares relating to its share-based programs. In April 2017, Abbott's shareholders authorized the 2017 Incentive Stock Program under which a maximum of 170 million shares were available for issuance. At December 31, 2017, approximately 169 million shares remained available for future issuance. The number of restricted stock awards and units outstanding and the weighted-average grant-date fair value at December 31, 2017 and December 31, 2016 was 15,518,719 and $42.82 and 13,705,511 and $41.03, respectively. The number of restricted stock awards and units, and the weighted-average grant-date fair value, that were granted, converted, vested and lapsed during 2017 were 8,267,212 and $45.20, 2,324,500 and $37.69, 7,553,969 and $40.77 and 1,224,535 and $41.76, respectively. The fair market value of restricted stock awards and units vested in 2017, 2016 and 2015 was $348 million, $225 million and $312 million, respectively. Options Outstanding Exercisable Options Shares Weighted Weighted Shares Weighted Weighted December 31, 2016 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted Converted for St. Jude Medical Exercised ) Lapsed ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2017 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The aggregate intrinsic value of options outstanding and exercisable at December 31, 2017 were each $500 million. The total intrinsic value of options exercised in 2017, 2016 and 2015 was $233 million, $98 million and $167 million, respectively. The total unrecognized compensation cost related to all share-based compensation plans at December 31, 2017 amounted to approximately $291 million, which is expected to be recognized over the next three years. Total non-cash stock compensation expense charged against income from continuing operations in 2017, 2016 and 2015 for share-based plans totaled approximately $406 million, $310 million and $291 million, respectively, and the tax benefit recognized was approximately $242 million, $100 million and $98 million, respectively. The increase in the 2017 tax benefit primarily relates to the $120 million of tax benefit recorded in income after the adoption of ASU 2016-09. Stock compensation cost capitalized as part of inventory is not significant. The fair value of an option granted in 2017, 2016 and 2015 was $6.54, $4.38, and $6.67, respectively. The fair value of an option grant was estimated using the Black-Scholes option-pricing model with the following assumptions: 2017 2016 2015 Risk-free interest rate % % % Average life of options (years) Volatility % % % Dividend yield % % % The risk-free interest rate is based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option's expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on Abbott's stock and historical volatility of Abbott's stock over the expected life of the option. Dividend yield is based on the option's exercise price and annual dividend rate at the time of grant. |
Debt and Lines of Credit
Debt and Lines of Credit | 12 Months Ended |
Dec. 31, 2017 | |
Debt and Lines of Credit | |
Debt and Lines of Credit | Note 10 — Debt and Lines of Credit The following is a summary of long-term debt at December 31: ( in millions ) 2017 2016 5.125% Notes, due 2019 $ $ 2.35% Notes, due 2019 2.50% Line of credit borrowing due 2019 — 2.80% Notes, due 2020 — 4.125% Notes, due 2020 2.00% Notes, due 2020 2.90% Notes, due 2021 2.55% Notes, due 2022 2.62% Term loan due 2022 — 3.25% Notes, due 2023 — 3.40% Notes, due 2023 3.875% Notes, due 2025 — 2.95% Notes, due 2025 3.75% Notes, due 2026 4.75% Notes, due 2036 6.15% Notes, due 2037 6.0% Notes, due 2039 5.3% Notes, due 2040 4.75% Notes, due 2043 — 4.90% Notes, due 2046 Unamortized debt issuance costs ) ) Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total, net of current maturities Current maturities of long-term debt ​ ​ ​ ​ ​ ​ ​ ​ Total carrying amount $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ In the first quarter of 2017, as part of the acquisition of St. Jude Medical, Abbott's long-term debt increased due to the assumption of outstanding debt previously issued by St. Jude Medical. Abbott exchanged certain St. Jude Medical debt obligations with an aggregate principal amount of approximately $2.9 billion for debt issued by Abbott which consists of: Principal Amount 2.00% Senior Notes due 2018 $ 473.8 million 2.80% Senior Notes due 2020 $ 483.7 million 3.25% Senior Notes due 2023 $ 818.4 million 3.875% Senior Notes due 2025 $ 490.7 million 4.75% Senior Notes due 2043 $ 639.1 million Following this exchange, approximately $194.2 million of existing St. Jude Medical notes remain outstanding across the five series of existing notes which have the same coupons and maturities as those listed above. There were no significant costs associated with the exchange of debt. In addition, during the first quarter of 2017, Abbott assumed and subsequently repaid approximately $2.8 billion of various St. Jude Medical debt obligations. On January 4, 2017, as part of funding the cash portion of the St. Jude Medical acquisition, Abbott borrowed $2.0 billion under a 120-day senior unsecured bridge term loan facility. This facility was repaid during the first quarter of 2017. In 2017, Abbott issued 364-day yen-denominated debt, of which $195 million was outstanding at December 31, 2017. Abbott also paid off a $479 million yen-denominated short-term borrowing during the year. On July 31, 2017, Abbott entered into a 5-year term loan agreement that allowed Abbott to borrow up to $2.8 billion on an unsecured basis for the acquisition of Alere. On October 3, 2017, Abbott borrowed $2.8 billion under this term loan agreement to finance the acquisition of Alere, to repay certain indebtedness of Abbott and Alere, and to pay fees and expenses in connection with the acquisition. Borrowings under the term loan bore interest based on a Eurodollar rate, plus an applicable margin based on Abbott's credit ratings. Abbott paid off this term loan on January 5, 2018. On October 3, 2017 Abbott borrowed $1.7 billion under its lines of credit. Proceeds from such borrowing were used to finance the acquisition of Alere, to repay certain indebtedness of Abbott and Alere, and to pay fees and expenses in connection with the acquisition. These lines of credit are part of a 2014 revolving credit agreement that provides Abbott with the ability to borrow up to $5 billion on an unsecured basis. Advances under the revolving credit agreement, including the $1.7 billion borrowing in October 2017, will mature and be payable on July 10, 2019. The $1.7 billion borrowing bore interest based on a Eurodollar rate, plus an applicable margin based on Abbott's credit ratings. Prior to October 3, 2017, no amounts were previously drawn under the revolving credit agreement. In the fourth quarter of 2017, Abbott paid off $550 million on the revolving loan. Abbott paid off the remaining balance on this revolving loan on January 5, 2018. In the fourth quarter of 2017, in conjunction with the acquisition of Alere, Abbott assumed and subsequently repaid $3.0 billion of Alere's debt. In November 2016, Abbott issued $15.1 billion of medium and long-term debt to primarily fund the cash portion of the acquisition of St. Jude Medical. Abbott issued $2.85 billion of 2.35% Senior Notes due November 22, 2019; $2.85 billion of 2.90% Senior Notes due November 30, 2021; $1.50 billion of 3.40% Senior Notes due November 30, 2023; $3.00 billion of 3.75% Senior Notes due November 30, 2026; $1.65 billion of 4.75% Senior Notes due November 30, 2036; and $3.25 billion of 4.90% Senior Notes due November 30, 2046. In November 2016, Abbott also entered into interest rate swap contracts totaling $3.0 billion related to the new debt, which have the effect of changing Abbott's obligation from a fixed interest rate to a variable interest rate obligation on the related debt instruments. In March 2015, Abbott issued $2.5 billion of long-term debt consisting of $750 million of 2.00% Senior Notes due March 15, 2020; $750 million of 2.55% Senior Notes due March 15, 2022; and $1.0 billion of 2.95% Senior Notes due March 15, 2025. Proceeds from this debt were used to pay down short-term borrowings. Abbott also entered into interest rate swap contracts totaling $2.5 billion, of which $1.5 billion was unwound in 2017. These contracts have the effect of changing Abbott's obligation from a fixed interest rate to a variable interest rate obligation. Principal payments required on long-term debt outstanding at December 31, 2017 are $508 million in 2018, $5.0 billion in 2019, $1.8 billion in 2020, $2.9 billion in 2021, $3.6 billion in 2022 and $14.3 billion in 2023 and thereafter. At December 31, 2017, Abbott's long-term debt rating was BBB by Standard & Poor's Corporation and Baa3 by Moody's Investors Service (Moody's). In February 2018, Moody's raised Abbott's rating to Baa2 with a positive outlook. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2019 and that support commercial paper borrowing arrangements. Abbott's weighted-average interest rate on short-term borrowings was 0.3% at December 31, 2017, 0.6% at December 31, 2016 and 0.2% at December 31, 2015. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $9 billion in conjunction with its pending acquisition of Alere. This commitment, which was automatically extended for up to 90 days on January 29, 2017, expired on April 30, 2017 and was not renewed since Abbott did not need this bridge facility to finance the Alere acquisition. The fees associated with the bridge facilities were recognized in interest expense. |
Financial Instruments, Derivati
Financial Instruments, Derivatives and Fair Value Measures | 12 Months Ended |
Dec. 31, 2017 | |
Financial Instruments, Derivatives and Fair Value Measures | |
Financial Instruments, Derivatives and Fair Value Measures | Note 11 — Financial Instruments, Derivatives and Fair Value Measures Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with notional amounts totaling $3.3 billion at December 31, 2017, and $2.6 billion at December 31, 2016, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. At December 31, 2016, $107 million of the notional amount related to AMO, a business that was divested in the first quarter of 2017. Accumulated gains and losses as of December 31, 2017 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months. The amount of hedge ineffectiveness was not significant in 2017, 2016 and 2015. Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen. At December 31, 2017, 2016 and 2015, Abbott held notional amounts of $20.1 billion, $14.9 billion and $14.0 billion, respectively, of such foreign currency forward exchange contracts. At December 31, 2016, $1.2 billion of the contracts related to AMO, a business that was divested in the first quarter of 2017. In March 2017, Abbott repaid its $479 million foreign denominated short-term debt which was designated as a hedge of the net investment in a foreign subsidiary. At December 31, 2016 and 2015, the value of this short-term debt was $454 million and $439 million, respectively, and changes in the fair value of the debt up through the date of repayment due to changes in exchange rates were recorded in Accumulated other comprehensive income (loss), net of tax. Abbott is a party to interest rate hedge contracts totaling notional amounts of $4.0 billion at December 31, 2017, $5.5 billion at December 31, 2016 and $4.0 billion at December 31, 2015, to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No hedge ineffectiveness was recorded in income in 2017, 2016 and 2015 for these hedges. In the second quarter of 2017, Abbott unwound approximately $1.5 billion in interest rate swaps relating to the 2.00% Note due in 2020 and the 2.55% Note due in 2022. The proceeds received were not significant. In December 2016, Abbott unwound approximately $1.5 billion in interest rate swaps relating to the 4.125% Note due in 2020 and the 5.125% Note due in 2019. As part of the unwinding, Abbott received approximately $55 million in cash, which was included in the Cash Flow From Financing Activities section of the Consolidated Statement of Cash Flows in 2016. Gross unrealized holding gains (losses) on available-for-sale equity securities totaled $(5) million, $10 million and $171 million at December 31, 2017, 2016 and 2015, respectively. The following table summarizes the amounts and location of certain derivative financial instruments as of December 31: Fair Value — Assets Fair Value — Liabilities 2017 2016 Balance Sheet Caption 2017 2016 Balance Sheet Caption (in millions) Interest rate swaps designated as fair value hedges $ — $ Deferred income taxes and other assets $ $ Post-employment obligations and other long-term liabilities Foreign currency forward exchange contracts — Hedging instruments Other prepaid expenses and receivables Other accrued liabilities Others not designated as hedges Other prepaid expenses and receivables Other accrued liabilities Debt designated as a hedge of net investment in a foreign subsidiary — — n/a — Short-term borrowings ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income. The amount of hedge ineffectiveness was not significant in 2017, 2016 and 2015 for these hedges. Gain (loss) Recognized in Income (expense) and Income Statement 2017 2016 2015 2017 2016 2015 (in millions) Foreign currency forward exchange contracts designated as cash flow hedges $ ) $ $ $ ) $ $ Cost of products sold Debt designated as a hedge of net investment in a foreign subsidiary ) ) — — — n/a Interest rate swaps designated as fair value hedges n/a n/a n/a ) ) Interest expense Losses of $64 million, gains of $8 million and losses of $77 million were recognized in 2017, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as hedges. These amounts are reported in the Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line. The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market. The carrying values and fair values of certain financial instruments as of December 31 are shown in the table below. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties. 2017 2016 Carrying Fair Carrying Fair (in millions) Long-term Investment Securities: Equity securities $ $ $ $ Other Total Long-term Debt ) ) ) ) Foreign Currency Forward Exchange Contracts: Receivable position (Payable) position ) ) ) ) Interest Rate Hedge Contracts: Receivable position — — (Payable) position ) ) ) ) The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet: Basis of Fair Value Measurement Outstanding Quoted Significant Other Significant (in millions) December 31, 2017: Equity securities $ $ $ — $ — Foreign currency forward exchange contracts — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Assets $ $ $ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of hedged long-term debt $ $ — $ $ — Interest rate swap financial instruments — — Foreign currency forward exchange contracts — — Contingent consideration related to business combinations — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Liabilities $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2016: Equity securities $ $ $ — $ — Interest rate swap financial instruments — — Foreign currency forward exchange contracts — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Assets $ $ $ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of hedged long-term debt $ $ — $ $ — Interest rate swap financial instruments — — Foreign currency forward exchange contracts — — Contingent consideration related to business combinations — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Liabilities $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The decrease in equity securities in 2017 was driven by the sale of the remaining Mylan N.V. ordinary shares held by Abbott. Abbott sold 69.75 million ordinary shares of Mylan N.V. in 2017 which had a value of approximately $2.7 billion. The fair value of the Mylan N.V. equity securities up through the date of sale was determined based on the value of the publicly-traded ordinary shares. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of the debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines. Contingent consideration relates to businesses acquired by Abbott. The maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales. Excluding such contingent consideration, the maximum amount estimated to be due is approximately $525 million, which is dependent upon attaining certain sales thresholds or based on the occurrence of certain events, such as regulatory approvals. |
Litigation and Environmental Ma
Litigation and Environmental Matters | 12 Months Ended |
Dec. 31, 2017 | |
Litigation and Environmental Matters | |
Litigation and Environmental Matters | Note 12 — Litigation and Environmental Matters Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million. Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $115 million to $160 million. The recorded accrual balance at December 31, 2017 for these proceedings and exposures was approximately $135 million. This accrual represents management's best estimate of probable loss, as defined by FASB ASC No. 450, "Contingencies." Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations. |
Post-Employment Benefits
Post-Employment Benefits | 12 Months Ended |
Dec. 31, 2017 | |
Post-Employment Benefits | |
Post-Employment Benefits | Note 13 — Post-Employment Benefits Retirement plans consist of defined benefit, defined contribution and medical and dental plans. Information for Abbott's major defined benefit plans and post-employment medical and dental benefit plans is as follows: Defined Benefit Medical and (in millions) 2017 2016 2017 2016 Projected benefit obligations, January 1 $ $ $ $ Service cost — benefits earned during the year Interest cost on projected benefit obligations (Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs Benefits paid ) ) ) ) Other, including foreign currency translation ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Projected benefit obligations, December 31 $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Plan assets at fair value, January 1 $ $ $ $ Actual return on plans' assets Company contributions Benefits paid ) ) ) ) Other, including foreign currency translation ) — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Plan assets at fair value, December 31 $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Projected benefit obligations greater than plan assets, December 31 $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term assets $ $ $ — $ — Short-term liabilities ) ) ) ) Long-term liabilities ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net liability $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts Recognized in Accumulated Other Comprehensive Income (loss): Actuarial losses, net $ $ $ $ Prior service cost (credits) ) — ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The projected benefit obligations for non-U.S. defined benefit plans was $3.0 billion and $2.5 billion at December 31, 2017 and 2016, respectively. The accumulated benefit obligations for all defined benefit plans were $8.9 billion and $7.4 billion at December 31, 2017 and 2016, respectively. For plans where the accumulated benefit obligations exceeded plan assets at December 31, 2017 and 2016, the aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets were as follows: (in millions) 2017 2016 Accumulated benefit obligation $ $ Projected benefit obligation Fair value of plan assets The components of the net periodic benefit cost were as follows: Defined Benefit Plans Medical and 2017 2016 2015 2017 2016 2015 (in millions) Service cost — benefits earned during the year $ $ $ $ $ $ Interest cost on projected benefit obligations Expected return on plans' assets ) ) ) ) ) ) Amortization of actuarial losses Amortization of prior service cost (credits) — ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total cost Less: Discontinued operations — — ) — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net cost — continuing operations $ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ In 2017, Abbott recognized a $10 million curtailment gain related to the sale of AMO. Other comprehensive income (loss) for each respective year includes the amortization of actuarial losses and prior service costs (credits) as noted in the previous table. Other comprehensive income (loss) for each respective year also includes: net actuarial losses of $247 million for defined benefit plans and $97 million for medical and dental plans in 2017; net actuarial losses of $571 million for defined benefit plans and $20 million for medical and dental plans in 2016; net actuarial gains of $37 million for defined benefit plans and $116 million for medical and dental plans in 2015. The pretax amount of actuarial losses and prior service cost (credits) included in Accumulated other comprehensive income (loss) at December 31, 2017 that is expected to be recognized in the net periodic benefit cost in 2018 is $213 million and $1 million of expense, respectively, for defined benefit pension plans and $31 million of expense and $45 million of income, respectively, for medical and dental plans. The weighted average assumptions used to determine benefit obligations for defined benefit plans and medical and dental plans are as follows: 2017 2016 2015 Discount rate % % % Expected aggregate average long-term change in compensation % % % The weighted average assumptions used to determine the net cost for defined benefit plans and medical and dental plans are as follows: 2017 2016 2015 Discount rate % % % Expected return on plan assets % % % Expected aggregate average long-term change in compensation % % % The assumed health care cost trend rates for medical and dental plans at December 31 were as follows: 2017 2016 2015 Health care cost trend rate assumed for the next year % % % Rate that the cost trend rate gradually declines to % % % Year that rate reaches the assumed ultimate rate The discount rates used to measure liabilities were determined based on high-quality fixed income securities that match the duration of the expected retiree benefits. The health care cost trend rates represent Abbott's expected annual rates of change in the cost of health care benefits and are forward projections of health care costs as of the measurement date. A one-percentage point increase/(decrease) in the assumed health care cost trend rate would increase/(decrease) the accumulated post-employment benefit obligations as of December 31, 2017, by $179 million /$(150) million, and the total of the service and interest cost components of net post-employment health care cost for the year then ended by approximately $11 million/$(9) million. The following table summarizes the basis used to measure the defined benefit and medical and dental plan assets at fair value: Basis of Fair Value Measurement Outstanding Quoted Significant Significant Measured at (in millions) December 31, 2017: Equities: U.S. large cap (a) $ $ $ — $ — $ U.S. mid and small cap (b) — — International (c) — — Fixed income securities: U.S. government securities (d) — Corporate debt instruments (e) — Non-U.S. government securities (f) — — Other (g) — Absolute return funds (h) — — Commodities (i) — — Cash and Cash Equivalents — — Other (j) — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2016: Equities: U.S. large cap (a) $ $ $ — $ — $ U.S. mid and small cap (b) — — International (c) — — Fixed income securities: U.S. government securities (d) — Corporate debt instruments (e) — Non-U.S. government securities (f) — — Other (g) — Absolute return funds (h) — — Commodities (i) — — Cash and Cash Equivalents — — Other (j) — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. (b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices. (c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. (d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices. (e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices. (f) Primarily United Kingdom, Japan, the Netherlands and Irish government-issued bonds. (g) Primarily asset backed securities and an actively managed, diversified fixed income vehicle benchmarked to the one-month Libor / Euribor. (h) Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets. (i) Primarily investments in liquid commodity future contracts and private energy funds. (j) Primarily investments in private funds, such as private equity, private credit and private real estate. (k) In accordance with ASU 2015-07, investments measured at fair value using the NAV practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet. Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective trust or a registered investment company that are valued using significant other observable inputs are valued at the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund minus its liabilities. For approximately half of these funds, investments may be redeemed once per month, with a required 7 to 30 day notice period. For the remaining funds, daily redemption of an investment is allowed. Fixed income securities that are valued using significant other observable inputs are valued at prices obtained from independent financial service industry recognized vendors. Abbott did not have any unfunded commitments related to fixed income funds at December 31, 2017 and 2016. For the majority of these funds, investments may be redeemed either weekly or monthly, with a required 2 to 14 day notice period. For the remaining funds, investments may be generally redeemed daily. Absolute return funds and commodities are valued at the NAV provided by the fund administrator. All private funds are valued at the NAV provided by the fund on a one-quarter lag adjusted for known cash flows and significant events through the reporting date. Abbott did not have any unfunded commitments related to absolute return funds at December 31, 2017 and 2016. Investments in these funds may be generally redeemed monthly or quarterly with required notice periods ranging from 5 to 45 days. For approximately $100 million of the absolute return funds, redemptions are subject to a 25% gate. For commodities, investments in the private energy funds cannot be redeemed but the funds will make distributions through liquidation. The estimate of the liquidation period for each fund ranges from 2018 to 2022. Abbott's unfunded commitments in these funds as of December 31, 2017 and 2016 were not significant. Investments in the private funds (excluding private energy funds) cannot be redeemed but the funds will make distributions through liquidation. The estimate of the liquidation period for each fund ranges from 2018 to 2027. Abbott's unfunded commitment in these funds was $489 million and $337 million as of December 31, 2017 and 2016, respectively. The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a desired return, as well as balancing higher return, more volatile equity securities with lower return, less volatile fixed income securities. Investment allocations are made across a range of markets, industry sectors, capitalization sizes, and in the case of fixed income securities, maturities and credit quality. The plans do not directly hold any securities of Abbott. There are no known significant concentrations of risk in the plans' assets. Abbott's medical and dental plans' assets are invested in a similar mix as the pension plan assets. The actual asset allocation percentages at year end are consistent with the company's targeted asset allocation percentages. The plans' expected return on assets, as shown above is based on management's expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, management considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic and capital market conditions. Abbott funds its domestic pension plans according to IRS funding limitations. International pension plans are funded according to similar regulations. Abbott funded $645 million in 2017 and $582 million in 2016 to defined pension plans. Abbott expects to contribute approximately $114 million to its pension plans in 2018. Total benefit payments expected to be paid to participants, which includes payments funded from company assets, as well as paid from the plans, are as follows: (in millions) Defined Medical and 2018 $ $ 2019 2020 2021 2022 2023 to 2027 The Abbott Stock Retirement Plan is the principal defined contribution plan. Abbott's contributions to this plan were $79 million in 2017, $83 million in 2016 and $81 million in 2015. |
Taxes on Earnings from Continui
Taxes on Earnings from Continuing Operations | 12 Months Ended |
Dec. 31, 2017 | |
Taxes on Earnings from Continuing Operations | |
Taxes on Earnings from Continuing Operations | Note 14 — Taxes on Earnings from Continuing Operations Taxes on earnings from continuing operations reflect the annual effective rates, including charges for interest and penalties. Deferred income taxes reflect the tax consequences on future years of differences between the tax bases of assets and liabilities and their financial reporting amounts. The Tax Cuts and Jobs Act ("TCJA") was enacted in the U.S. on December 22, 2017. The TCJA reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. In the fourth quarter of 2017, Abbott recorded an estimate of net tax expense of $1.46 billion for the impact of the TCJA, which is included in Taxes on Earnings from Continuing Operations in the Consolidated Statement of Earnings. The estimate is provisional and includes a charge of approximately $2.89 billion for the transition tax, partially offset by a net benefit of approximately $1.42 billion for the remeasurement of deferred tax assets and liabilities and a net benefit of approximately $10 million related to certain other impacts of the TCJA. The one-time transition tax is based on Abbott's total post-1986 earnings and profits (E&P) that were previously deferred from U.S. income taxes. Abbott has not yet completed its calculation of the total post-1986 E&P for its foreign subsidiaries. The tax computation also requires the determination of the amount of post-1986 E&P considered held in cash and other specified assets. This amount may change as Abbott finalizes the calculation of post-1986 foreign E&P previously deferred from U.S. federal taxation and finalizes the amounts held in cash and other specified assets. Abbott plans to elect to pay the transition tax over eight years as allowed by the TCJA. Given the significant complexity of the TCJA, Abbott will continue to evaluate and analyze the impact of this legislation. The $1.46 billion estimate is provisional and is based on Abbott's initial analysis of the TCJA and may be materially adjusted in future periods due to among other things, additional analysis performed by Abbott and additional guidance that may be issued by the U.S. Department of Treasury, the Securities and Exchange Commission, or the Financial Accounting Standards Board. In 2017, taxes on earnings from continuing operations also include $435 million of tax expense related to the gain on the sale of the AMO business. In 2016, taxes on earnings from continuing operations include the impact of a net tax benefit of approximately $225 million, primarily as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela and the adjustment of the Mylan N.V. equity investment, as well as the recognition of deferred taxes associated with the then pending sale of AMO. In 2015, taxes on earnings from continuing operations include a tax cost of $71 million related to the disposal of shares of Mylan N.V. stock. No additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities is not practicable. In the U.S., Abbott's federal income tax returns through 2013 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through 2012. There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. Reserves for interest and penalties are not significant. Earnings from continuing operations before taxes, and the related provisions for taxes on earnings from continuing operations, were as follows: (in millions) 2017 2016 2015 Earnings From Continuing Operations Before Taxes: Domestic $ $ $ Foreign ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in millions) 2017 2016 2015 Taxes on Earnings From Continuing Operations: Current: Domestic $ $ $ Foreign ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total current ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred: Domestic ) ) Foreign ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total deferred ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Differences between the effective income tax rate and the U.S. statutory tax rate were as follows: 2017 2016 2015 Statutory tax rate on earnings from continuing operations % % % Impact of foreign operations ) ) ) Impact of TCJA — — Excess tax benefits related to stock compensation ) — — Research tax credit ) ) ) Resolution of certain tax positions pertaining to prior years — ) — Mylan share adjustment — — State taxes, net of federal benefit ) Federal tax cost on sale of Mylan N.V. shares — All other, net ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Effective tax rate on earnings from continuing operations % % % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Impact of foreign operations is primarily derived from operations in Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica, and Singapore. The 2015 effective tax rate includes the impact of the R&D tax credit that was made permanent in the U.S. by the Protecting Americans from Tax Hikes Act of 2015. The tax effect of the differences that give rise to deferred tax assets and liabilities were as follows: (in millions) 2017 2016 Deferred tax assets: Compensation and employee benefits $ $ Other, primarily reserves not currently deductible, and NOL's and credit carryforwards Trade receivable reserves Inventory reserves Deferred intercompany profit State income taxes ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets before valuation allowance Valuation allowance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities: Depreciation ) ) Unremitted earnings of foreign subsidiaries — ) Other, primarily the excess of book basis over tax basis of intangible assets ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax liabilities ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total net deferred tax assets (liabilities) $ ) $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Abbott has incurred losses in a foreign jurisdiction where realization of the future economic benefit is so remote that the benefit is not reflected as a deferred tax asset. The increase in the valuation allowance from 2016 to 2017 relates to deferred tax assets recorded in certain entities acquired as part of the acquisition of St. Jude Medical. Abbott does not believe that it is more likely than not that the benefits of these deferred tax assets will be realized. The following table summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled: (in millions) 2017 2016 January 1 $ $ Increase in tax positions due to acquisitions — Increase due to current year tax positions Increase due to prior year tax positions Decrease due to prior year tax positions ) ) Settlements ) ) Lapse of statute ) — ​ ​ ​ ​ ​ ​ ​ ​ December 31 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The total amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate is approximately $1.36 billion. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease within a range of $150 million to $300 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. |
Segment and Geographic Area Inf
Segment and Geographic Area Information | 12 Months Ended |
Dec. 31, 2017 | |
Segment and Geographic Area Information | |
Segment and Geographic Area Information | Note 15 — Segment and Geographic Area Information Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott's products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies throughout the world. On January 4, 2017, Abbott completed the acquisition of St. Jude Medical. Beginning with the first quarter of 2017, Abbott's cardiovascular and neuromodulation business includes the results of its historical Vascular Products segment and the results of the businesses acquired from St. Jude Medical from the date of acquisition. On October 3, 2017, Abbott completed the acquisition of Alere. Beginning with the fourth quarter of 2017, Abbott's Diagnostic Products reportable segment includes the results of Alere from the date of acquisition. Abbott's reportable segments are as follows: Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products. Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products. Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care, Rapid Diagnostics and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment. Rapid Diagnostics is the business acquired from Alere. Cardiovascular and Neuromodulation Products — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart and neuromodulation products. Non-reportable segments include AMO through the date of sale and Diabetes Care. Abbott's underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment's assets. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements. Net Sales to External Customers (a) Operating Earnings (a) (in millions) 2017 2016 2015 2017 2016 2015 Established Pharmaceuticals $ $ $ $ $ $ Nutritionals Diagnostics Cardiovascular and Neuromodulation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Reportable Segments $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) Net sales were unfavorably affected by the relatively stronger U.S. dollar in 2016 and 2015. Operating earnings were unfavorably affected by the impact of foreign exchange in 2017, 2016 and 2015. 2017 2016 2015 (in millions) Total Reportable Segment Operating Earnings $ $ $ Corporate functions and benefit plans costs ) ) ) Non-reportable segments Net interest expense ) ) ) Share-based compensation ) ) ) Amortization of intangible assets ) ) ) Other, net (b) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings from Continuing Operations before Taxes $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (b) Other, net includes inventory step-up amortization, integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges, partially offset by the gain on the sale of the AMO business in 2017. In 2016, Other, net includes the $947 million adjustment of the Mylan equity investment and $480 million of foreign currency exchange loss related to operations in Venezuela. Charges for restructuring actions and other cost reduction initiatives were approximately $384 million in 2017, $167 million in 2016 and $310 million in 2015. 2015 includes a $207 million pre-tax gain on the sale of a portion of the Mylan N.V. ordinary shares. Depreciation Additions to Total Assets (in millions) 2017 2016 2015 2017 2016 2015 2017 2016 2015 Established Pharmaceuticals $ $ $ $ $ $ $ $ $ Nutritionals Diagnostics Cardiovascular and Neuromodulation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Reportable Segments $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (c) Amounts exclude property, plant and equipment acquired through business acquisitions. 2017 2016 2015 (in millions) Total Reportable Segment Assets $ $ $ Cash and investments Non-reportable segments Goodwill and intangible assets (d) All other (d) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Assets $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (d) Goodwill and intangible assets related to AMO are included in the All other line in 2016. Net Sales to External 2017 2016 2015 (in millions) United States $ $ $ China Germany Japan India The Netherlands Switzerland Russia France Brazil Italy United Kingdom Colombia Canada Vietnam All Other Countries ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (e) Sales by country are based on the country that sold the product. Long-lived assets on a geographic basis primarily include property, plant and equipment. It excludes goodwill, intangible assets, deferred tax assets, and financial instruments. At December 31, 2017 and 2016, Long-lived assets totaled $8.9 billion and $6.6 billion, respectively, and in the United States such assets totaled $4.5 billion and $3.1 billion, respectively. Long-lived asset balances associated with other countries were not material on an individual country basis in either of the two years |
Quarterly Results (Unaudited)
Quarterly Results (Unaudited) | 12 Months Ended |
Dec. 31, 2017 | |
Quarterly Results (Unaudited) | |
Quarterly Results (Unaudited) | Note 16 — Quarterly Results (Unaudited) (in millions except per share data) 2017 2016 First Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings from Continuing Operations Basic Earnings per Common Share Diluted Earnings per Common Share Net Earnings Basic Earnings Per Common Share (a) Diluted Earnings Per Common Share (a) Market Price Per Share-High Market Price Per Share-Low Second Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings from Continuing Operations Basic Earnings per Common Share Diluted Earnings per Common Share Net Earnings Basic Earnings Per Common Share (a) Diluted Earnings Per Common Share (a) Market Price Per Share-High Market Price Per Share-Low Third Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings (Loss) from Continuing Operations ) Basic Earnings (Loss) per Common Share ) Diluted Earnings (Loss) per Common Share ) Net Earnings (Loss) ) Basic Earnings (Loss) Per Common Share (a) ) Diluted Earnings (Loss) Per Common Share (a) ) Market Price Per Share-High Market Price Per Share-Low Fourth Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings (Loss) from Continuing Operations ) Basic Earnings (Loss) per Common Share ) Diluted Earnings (Loss) per Common Share ) Net Earnings (Loss) ) Basic Earnings (Loss) Per Common Share (a) ) Diluted Earnings (Loss) Per Common Share (a) ) Market Price Per Share-High Market Price Per Share-Low (a) The sum of the four quarters of earnings per share for 2017 and 2016 may not add to the full year earnings per share amount due to rounding and/or the use of quarter-to-date weighted average shares to calculate the earnings per share amount in each respective quarter. |
Summary of Significant Accoun26
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Summary of Significant Accounting Policies | |
NATURE OF BUSINESS | NATURE OF BUSINESS — Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. |
CHANGES IN PRESENTATION | CHANGES IN PRESENTATION — In September 2016, Abbott announced that it had entered into an agreement to sell Abbott Medical Optics (AMO), its vision care business, to Johnson & Johnson. The transaction closed in February 2017. The operating results of AMO up to the date of sale were reported as part of continuing operations as AMO did not qualify for reporting as a discontinued operation. The assets and liabilities of AMO are reported as held for disposition in Abbott's Consolidated Balance Sheet at December 31, 2016. On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for equity ownership of a newly formed entity that combined Mylan's existing business and Abbott's developed markets pharmaceuticals business. On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. The historical operating results of these two businesses up to the date of sale are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations, net of taxes line in Abbott's Consolidated Statement of Earnings. The cash flows of these businesses are included in Abbott's Consolidated Statement of Cash Flows up to the date of disposition. See Note 2 — Discontinued Operations for additional information. |
BASIS OF CONSOLIDATION | BASIS OF CONSOLIDATION — The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. |
USE OF ESTIMATES | USE OF ESTIMATES — The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for sales rebates; income taxes; pension and other post-employment benefits, including certain asset values that are based on significant unobservable inputs; valuation of intangible assets; litigation; derivative financial instruments; and inventory and accounts receivable exposures. |
FOREIGN CURRENCY TRANSLATION | FOREIGN CURRENCY TRANSLATION — The statements of earnings of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in equity as a component of Accumulated other comprehensive income (loss). Transaction gains and losses are recorded on the Net foreign exchange (gain) loss line of the Consolidated Statement of Earnings. |
REVENUE RECOGNITION | REVENUE RECOGNITION — Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Sales incentives to customers are not material. Historical data is readily available and reliable, and is used for estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer's normal requirements are recorded when the conditions noted above are met. In those situations, management records a returns reserve for such revenue, if necessary. In certain of Abbott's businesses, primarily within diagnostics and medical optics, prior to its divestiture, Abbott participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements). Under these arrangements, Abbott recognizes revenue upon delivery of the product or performance of the service and allocates the revenue based on the relative selling price of each deliverable, which is based primarily on vendor specific objective evidence. Sales of product rights for marketable products are recorded as revenue upon disposition of the rights. Revenue from license of product rights, or for performance of research or selling activities, is recorded over the periods earned. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers , which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for Abbott in the first quarter of 2018. Abbott's revenues are primarily comprised of product sales. Abbott completed a thorough evaluation of the new standard including a detailed review of Abbott's revenue streams and contracts. Abbott does not expect the adoption of the new standard to have a material impact on its consolidated financial statements. Abbott will use the modified retrospective method to adopt this standard. |
INCOME TAXES | INCOME TAXES — Deferred income taxes are provided for the tax effect of differences between the tax bases of assets and liabilities and their reported amounts in the financial statements at the enacted statutory rate to be in effect when the taxes are paid. No additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax related to the U.S. Tax Cuts and Jobs Act, or any additional outside basis differences that exist, as these amounts continue to be indefinitely reinvested in foreign operations. Interest and penalties on income tax obligations are included in taxes on income. |
EARNINGS PER SHARE | EARNINGS PER SHARE — Unvested restricted stock units and awards that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares in 2017, 2016 and 2015 were $346 million, $1.057 billion and $2.595 billion, respectively. Net earnings allocated to common shares in 2017, 2016 and 2015 were $468 million, $1.393 billion and $4.403 billion, respectively. |
PENSION AND POST-EMPLOYMENT BENEFITS | PENSION AND POST-EMPLOYMENT BENEFITS — Abbott accrues for the actuarially determined cost of pension and post-employment benefits over the service attribution periods of the employees. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on plan assets. Differences between the expected long-term return on plan assets and the actual return are amortized over a five-year period. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method. |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS — For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model. Purchased intangible assets are recorded at fair value. The fair value of significant purchased intangible assets is based on independent appraisals. Abbott uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Intangible assets are reviewed for impairment on a quarterly basis. Goodwill and indefinite-lived intangible assets are tested for impairment at least annually. |
SHARE-BASED COMPENSATION | SHARE-BASED COMPENSATION — The fair value of stock options and restricted stock awards and units are amortized over their requisite service period, which could be shorter than the vesting period if an employee is retirement eligible, with a charge to compensation expense. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . ASU 2016-09 modifies several aspects of the accounting for share-based payment transactions, including the accounting for income taxes and classification on the statement of cash flows. Abbott adopted the standard in the first quarter of 2017 and the following changes were made to the presentation of Abbott's financial statements: • All excess tax benefits or tax deficiencies are now recognized as income tax benefit or expense as applicable. Previously, Abbott recorded the benefits to Shareholders' Investment. The tax benefit recorded in Abbott's Consolidated Statement of Earnings for 2017 was $120 million. The standard does not permit retrospective presentation of this benefit in prior years. • The tax benefit or deficiency is required to be classified as an operating activity in the statement of cash flows. Previously, it was required to be classified within financing activities. Abbott has adopted this standard on a prospective basis and has not revised the classification of the excess tax benefit in the prior year's Consolidated Statement of Cash Flows. |
LITIGATION | LITIGATION — Abbott accounts for litigation losses in accordance with FASB ASC No. 450, "Contingencies." Under ASC No. 450, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. Legal fees are recorded as incurred. |
CASH, CASH EQUIVALENTS AND INVESTMENTS | CASH, CASH EQUIVALENTS AND INVESTMENTS — Cash equivalents consist of bank time deposits, U.S. government securities money market funds and U.S. treasury bills with original maturities of three months or less. Abbott holds certain investments with a carrying value of approximately $235 million that are accounted for under the equity method of accounting. Investments held in a rabbi trust are accounted for as trading securities. All other investments in marketable equity securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in Accumulated other comprehensive income (loss). Investments in equity securities that are not traded on public stock exchanges are recorded at cost. Investments in debt securities are classified as held-to-maturity, as management has both the intent and ability to hold these securities to maturity, and are reported at cost, net of any unamortized premium or discount. Income relating to these securities is reported as interest income. Abbott reviews the carrying value of investments each quarter to determine whether an other than temporary decline in fair value exists. Abbott considers factors affecting the investee, factors affecting the industry the investee operates in and general equity market trends. Abbott considers the length of time an investment's fair value has been below carrying value and the near-term prospects for recovery to carrying value. When Abbott determines that an other than temporary decline has occurred, the investment is written down with a charge to Other (income) expense, net. |
TRADE RECEIVABLE VALUATIONS | TRADE RECEIVABLE VALUATIONS — Accounts receivable are stated at their net realizable value. The allowance against gross trade receivables reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are charged off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. |
INVENTORIES | INVENTORIES — Inventories are stated at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. |
PROPERTY AND EQUIPMENT | PROPERTY AND EQUIPMENT — Depreciation and amortization are provided on a straight-line basis over the estimated useful lives of the assets. The following table shows estimated useful lives of property and equipment: Classification Estimated Useful Lives Buildings 10 to 50 years (average 27 years) Equipment 3 to 20 years (average 11 years) |
PRODUCT LIABILITY | PRODUCT LIABILITY — Abbott accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The liabilities are adjusted quarterly as additional information becomes available. Receivables for insurance recoveries for product liability claims are recorded as assets, on an undiscounted basis, when it is probable that a recovery will be realized. Product liability losses are self-insured. |
RESEARCH AND DEVELOPMENT COSTS | RESEARCH AND DEVELOPMENT COSTS — Internal research and development costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are achieved. |
ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) | ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) — The initial costs of rights to IPR&D projects obtained in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until completed and are then amortized over the remaining useful life. Collaborations are not significant. |
CONCENTRATION OF RISK AND GUARANTEES | CONCENTRATION OF RISK AND GUARANTEES — Due to the nature of its operations, Abbott is not subject to significant concentration risks relating to customers, products or geographic locations. Product warranties are not significant. Abbott has no material exposures to off-balance sheet arrangements; no special purpose entities; nor activities that include non-exchange-traded contracts accounted for at fair value. Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies, which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events. |
Summary of Significant Accoun27
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Summary of Significant Accounting Policies | |
Schedule of estimated useful lives of property and equipment | Classification Estimated Useful Lives Buildings 10 to 50 years (average 27 years) Equipment 3 to 20 years (average 11 years) |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Discontinued Operations | |
Schedule of components of discontinued operations | Year Ended (in millions) 2017 2016 2015 Net Sales Developed markets generics pharmaceuticals and animal health businesses $ — $ — $ AbbVie — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ — $ — $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings (Loss) Before Tax Developed markets generics pharmaceuticals and animal health businesses $ $ ) $ AbbVie — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ) $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Earnings Developed markets generics pharmaceuticals and animal health businesses $ $ $ AbbVie ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Assets and Liabilities Held f29
Assets and Liabilities Held for Disposition (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Assets and Liabilities Held for Disposition | |
Summary of assets and liabilities held for disposition | (in millions) December 31, December 31, Trade receivables, net $ $ Total inventories Prepaid expenses and other current assets — ​ ​ ​ ​ ​ ​ ​ ​ Current assets held for disposition ​ ​ ​ ​ ​ ​ ​ ​ Net property and equipment Intangible assets, net of amortization Goodwill Deferred income taxes and other assets — ​ ​ ​ ​ ​ ​ ​ ​ Non-current assets held for disposition ​ ​ ​ ​ ​ ​ ​ ​ Total assets held for disposition $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade accounts payable $ — $ Salaries, wages, commissions and other accrued liabilities — ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities held for disposition — Post-employment obligations, deferred income taxes and other long-term liabilities — ​ ​ ​ ​ ​ ​ ​ ​ Total liabilities held for disposition $ — $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Supplemental Financial Inform30
Supplemental Financial Information (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Supplemental Financial Information | |
Schedule of long-term investments | 2017 2016 (in millions) Long-term Investments: Equity securities $ $ Other ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of other accrued liabilities | 2017 2016 (in millions) Other Accrued Liabilities: Accrued rebates payable to government agencies $ $ Accrued other rebates (a) All other ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) Accrued wholesaler chargeback rebates of $178 million and $214 million at December 31, 2017 and 2016, respectively, are netted in trade receivables because Abbott's customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products. |
Schedule of post-employment obligations and other long-term liabilities | 2017 2016 (in millions) Post-employment Obligations and Other Long-term Liabilities: Defined benefit pension plans and post-employment medical and dental plans for significant plans $ $ Deferred income taxes All other (b) ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (b) 2017 includes approximately $835 million of net unrecognized tax benefits, as well as approximately $100 million of acquisition consideration payable. 2016 includes approximately $560 million of net unrecognized tax benefits, as well as approximately $130 million of acquisition consideration payable. |
Accumulated Other Comprehensi31
Accumulated Other Comprehensive Income (Loss) (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Accumulated Other Comprehensive Income (Loss) | |
Schedule of accumulated other comprehensive income (loss) | The components of the changes in accumulated other comprehensive income (loss) from continuing operations, net of income taxes, are as follows: ( in millions ) Cumulative Net Cumulative Cumulative Total Balance at December 31, 2015 $ ) $ ) $ $ $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive income (loss) before reclassifications ) ) ) ) (Income) loss amounts reclassified from accumulated other comprehensive income (a) — ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net current period other comprehensive income (loss) ) ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2016 ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Impact of business dispositions — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive income (loss) before reclassifications ) ) (Income) loss amounts reclassified from accumulated other comprehensive income (a) — ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net current period other comprehensive income (loss) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2017 $ ) $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) Reclassified amounts for foreign currency translation adjustments are recorded in the Consolidated Statement of Earnings as Net Foreign exchange (gain) loss; gains (losses) on marketable equity securities are recorded as Other (income) expense and gains/losses related to cash flow hedges are recorded as Cost of product sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan cost — see Note 13 for additional information. |
Business Acquisitions (Tables)
Business Acquisitions (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
St Jude Medical | |
Business Acquisitions | |
Schedule of allocation of fair value of the acquisition | (in billions) Acquired intangible assets, non-deductible $ Goodwill, non-deductible Acquired net tangible assets Deferred income taxes recorded at acquisition ) Net debt ) ​ ​ ​ ​ ​ Total final allocation of fair value $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Alere Inc | |
Business Acquisitions | |
Schedule of allocation of fair value of the acquisition | (in billions) Acquired intangible assets, non-deductible $ Goodwill, non-deductible Acquired net tangible assets Deferred income taxes recorded at acquisition ) Net debt ) Preferred stock ) ​ ​ ​ ​ ​ Total preliminary allocation of fair value $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Restructuring Plans (Tables)
Restructuring Plans (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Restructuring Plan 2017 | |
Restructuring costs | |
Summary of restructuring activity | The following summarizes the activity in 2017 related to these actions and the status of the related accrual as of December 31, 2017: (in millions) Liabilities assumed as part of business acquisitions $ Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2017 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Restructuring Plan from 2014 to 2017 | |
Restructuring costs | |
Summary of restructuring activity | (in millions) Restructuring charges recorded in 2014 $ Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2014 Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2015 Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2016 Restructuring charges Payments and other adjustments ) ​ ​ ​ ​ ​ Accrued balance at December 31, 2017 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Incentive Stock Program (Tables
Incentive Stock Program (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Incentive Stock Program | |
Schedule of stock options outstanding and exercisable | Options Outstanding Exercisable Options Shares Weighted Weighted Shares Weighted Weighted December 31, 2016 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted Converted for St. Jude Medical Exercised ) Lapsed ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2017 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of fair value assumptions used to estimate fair value of option | 2017 2016 2015 Risk-free interest rate % % % Average life of options (years) Volatility % % % Dividend yield % % % |
Debt and Lines of Credit (Table
Debt and Lines of Credit (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Debt and Lines of Credit | |
Summary of long-term debt | The following is a summary of long-term debt at December 31: ( in millions ) 2017 2016 5.125% Notes, due 2019 $ $ 2.35% Notes, due 2019 2.50% Line of credit borrowing due 2019 — 2.80% Notes, due 2020 — 4.125% Notes, due 2020 2.00% Notes, due 2020 2.90% Notes, due 2021 2.55% Notes, due 2022 2.62% Term loan due 2022 — 3.25% Notes, due 2023 — 3.40% Notes, due 2023 3.875% Notes, due 2025 — 2.95% Notes, due 2025 3.75% Notes, due 2026 4.75% Notes, due 2036 6.15% Notes, due 2037 6.0% Notes, due 2039 5.3% Notes, due 2040 4.75% Notes, due 2043 — 4.90% Notes, due 2046 Unamortized debt issuance costs ) ) Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total, net of current maturities Current maturities of long-term debt ​ ​ ​ ​ ​ ​ ​ ​ Total carrying amount $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of debt assumed and exchanged | Principal Amount 2.00% Senior Notes due 2018 $ 473.8 million 2.80% Senior Notes due 2020 $ 483.7 million 3.25% Senior Notes due 2023 $ 818.4 million 3.875% Senior Notes due 2025 $ 490.7 million 4.75% Senior Notes due 2043 $ 639.1 million |
Financial Instruments, Deriva36
Financial Instruments, Derivatives and Fair Value Measures (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Financial Instruments, Derivatives and Fair Value Measures | |
Summary of the amounts and location of certain derivative financial instruments | Fair Value — Assets Fair Value — Liabilities 2017 2016 Balance Sheet Caption 2017 2016 Balance Sheet Caption (in millions) Interest rate swaps designated as fair value hedges $ — $ Deferred income taxes and other assets $ $ Post-employment obligations and other long-term liabilities Foreign currency forward exchange contracts — Hedging instruments Other prepaid expenses and receivables Other accrued liabilities Others not designated as hedges Other prepaid expenses and receivables Other accrued liabilities Debt designated as a hedge of net investment in a foreign subsidiary — — n/a — Short-term borrowings ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of derivatives gain (loss) in OCI and earnings | Gain (loss) Recognized in Income (expense) and Income Statement 2017 2016 2015 2017 2016 2015 (in millions) Foreign currency forward exchange contracts designated as cash flow hedges $ ) $ $ $ ) $ $ Cost of products sold Debt designated as a hedge of net investment in a foreign subsidiary ) ) — — — n/a Interest rate swaps designated as fair value hedges n/a n/a n/a ) ) Interest expense |
Schedule of carrying values and fair values of certain financial instruments | 2017 2016 Carrying Fair Carrying Fair (in millions) Long-term Investment Securities: Equity securities $ $ $ $ Other Total Long-term Debt ) ) ) ) Foreign Currency Forward Exchange Contracts: Receivable position (Payable) position ) ) ) ) Interest Rate Hedge Contracts: Receivable position — — (Payable) position ) ) ) ) |
Schedule of assets and liabilities measured at fair value on a recurring basis | Basis of Fair Value Measurement Outstanding Quoted Significant Other Significant (in millions) December 31, 2017: Equity securities $ $ $ — $ — Foreign currency forward exchange contracts — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Assets $ $ $ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of hedged long-term debt $ $ — $ $ — Interest rate swap financial instruments — — Foreign currency forward exchange contracts — — Contingent consideration related to business combinations — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Liabilities $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2016: Equity securities $ $ $ — $ — Interest rate swap financial instruments — — Foreign currency forward exchange contracts — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Assets $ $ $ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value of hedged long-term debt $ $ — $ $ — Interest rate swap financial instruments — — Foreign currency forward exchange contracts — — Contingent consideration related to business combinations — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Liabilities $ $ — $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Post-Employment Benefits (Table
Post-Employment Benefits (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Post-Employment Benefits | |
Schedule of aggregate accumulated benefit obligations, projected benefit obligations and aggregate plan assets for plans whose accumulated benefit obligation exceeded plan assets | Defined Benefit Medical and (in millions) 2017 2016 2017 2016 Projected benefit obligations, January 1 $ $ $ $ Service cost — benefits earned during the year Interest cost on projected benefit obligations (Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs Benefits paid ) ) ) ) Other, including foreign currency translation ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Projected benefit obligations, December 31 $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Plan assets at fair value, January 1 $ $ $ $ Actual return on plans' assets Company contributions Benefits paid ) ) ) ) Other, including foreign currency translation ) — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Plan assets at fair value, December 31 $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Projected benefit obligations greater than plan assets, December 31 $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term assets $ $ $ — $ — Short-term liabilities ) ) ) ) Long-term liabilities ) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net liability $ ) $ ) $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amounts Recognized in Accumulated Other Comprehensive Income (loss): Actuarial losses, net $ $ $ $ Prior service cost (credits) ) — ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of plans where the accumulated benefit obligations exceeded plan assets the aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets | (in millions) 2017 2016 Accumulated benefit obligation $ $ Projected benefit obligation Fair value of plan assets |
Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans | Defined Benefit Plans Medical and 2017 2016 2015 2017 2016 2015 (in millions) Service cost — benefits earned during the year $ $ $ $ $ $ Interest cost on projected benefit obligations Expected return on plans' assets ) ) ) ) ) ) Amortization of actuarial losses Amortization of prior service cost (credits) — ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total cost Less: Discontinued operations — — ) — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net cost — continuing operations $ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of weighted average assumptions used to determine benefit obligations and net cost for defined benefit plans and medical and dental plans | The weighted average assumptions used to determine benefit obligations for defined benefit plans and medical and dental plans are as follows: 2017 2016 2015 Discount rate % % % Expected aggregate average long-term change in compensation % % % The weighted average assumptions used to determine the net cost for defined benefit plans and medical and dental plans are as follows: 2017 2016 2015 Discount rate % % % Expected return on plan assets % % % Expected aggregate average long-term change in compensation % % % |
Schedule of assumed health care cost trend rates | 2017 2016 2015 Health care cost trend rate assumed for the next year % % % Rate that the cost trend rate gradually declines to % % % Year that rate reaches the assumed ultimate rate |
Schedule of basis used to measure the defined benefit and medical and dental plan assets at fair value | Basis of Fair Value Measurement Outstanding Quoted Significant Significant Measured at (in millions) December 31, 2017: Equities: U.S. large cap (a) $ $ $ — $ — $ U.S. mid and small cap (b) — — International (c) — — Fixed income securities: U.S. government securities (d) — Corporate debt instruments (e) — Non-U.S. government securities (f) — — Other (g) — Absolute return funds (h) — — Commodities (i) — — Cash and Cash Equivalents — — Other (j) — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2016: Equities: U.S. large cap (a) $ $ $ — $ — $ U.S. mid and small cap (b) — — International (c) — — Fixed income securities: U.S. government securities (d) — Corporate debt instruments (e) — Non-U.S. government securities (f) — — Other (g) — Absolute return funds (h) — — Commodities (i) — — Cash and Cash Equivalents — — Other (j) — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. (b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices. (c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. (d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices. (e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices. (f) Primarily United Kingdom, Japan, the Netherlands and Irish government-issued bonds. (g) Primarily asset backed securities and an actively managed, diversified fixed income vehicle benchmarked to the one-month Libor / Euribor. (h) Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets. (i) Primarily investments in liquid commodity future contracts and private energy funds. (j) Primarily investments in private funds, such as private equity, private credit and private real estate. (k) In accordance with ASU 2015-07, investments measured at fair value using the NAV practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet. |
Benefit payments expected to be paid to participants | (in millions) Defined Medical and 2018 $ $ 2019 2020 2021 2022 2023 to 2027 |
Taxes on Earnings from Contin38
Taxes on Earnings from Continuing Operations (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Taxes on Earnings from Continuing Operations | |
Schedule of earnings from continuing operations before taxes | (in millions) 2017 2016 2015 Earnings From Continuing Operations Before Taxes: Domestic $ $ $ Foreign ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of components of Income Tax Expense (Benefit), Continuing Operations | (in millions) 2017 2016 2015 Taxes on Earnings From Continuing Operations: Current: Domestic $ $ $ Foreign ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total current ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred: Domestic ) ) Foreign ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total deferred ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of reconciliation of income taxes at the U.S. federal statutory rate to income tax expense (benefit) | 2017 2016 2015 Statutory tax rate on earnings from continuing operations % % % Impact of foreign operations ) ) ) Impact of TCJA — — Excess tax benefits related to stock compensation ) — — Research tax credit ) ) ) Resolution of certain tax positions pertaining to prior years — ) — Mylan share adjustment — — State taxes, net of federal benefit ) Federal tax cost on sale of Mylan N.V. shares — All other, net ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Effective tax rate on earnings from continuing operations % % % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of components of net deferred tax assets (liabilities) | (in millions) 2017 2016 Deferred tax assets: Compensation and employee benefits $ $ Other, primarily reserves not currently deductible, and NOL's and credit carryforwards Trade receivable reserves Inventory reserves Deferred intercompany profit State income taxes ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets before valuation allowance Valuation allowance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities: Depreciation ) ) Unremitted earnings of foreign subsidiaries — ) Other, primarily the excess of book basis over tax basis of intangible assets ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax liabilities ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total net deferred tax assets (liabilities) $ ) $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Schedule of reconciliation of unrecognized tax benefits for the period | (in millions) 2017 2016 January 1 $ $ Increase in tax positions due to acquisitions — Increase due to current year tax positions Increase due to prior year tax positions Decrease due to prior year tax positions ) ) Settlements ) ) Lapse of statute ) — ​ ​ ​ ​ ​ ​ ​ ​ December 31 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
Segment and Geographic Area I39
Segment and Geographic Area Information (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Segment and Geographic Area Information | |
Schedule of segment information - net sales and operating earnings | Net Sales to External Customers (a) Operating Earnings (a) (in millions) 2017 2016 2015 2017 2016 2015 Established Pharmaceuticals $ $ $ $ $ $ Nutritionals Diagnostics Cardiovascular and Neuromodulation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Reportable Segments $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (a) Net sales were unfavorably affected by the relatively stronger U.S. dollar in 2016 and 2015. Operating earnings were unfavorably affected by the impact of foreign exchange in 2017, 2016 and 2015. |
Schedule of reconciliation of operating earnings to earnings from continuing operations | 2017 2016 2015 (in millions) Total Reportable Segment Operating Earnings $ $ $ Corporate functions and benefit plans costs ) ) ) Non-reportable segments Net interest expense ) ) ) Share-based compensation ) ) ) Amortization of intangible assets ) ) ) Other, net (b) ) ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings from Continuing Operations before Taxes $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (b) Other, net includes inventory step-up amortization, integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges, partially offset by the gain on the sale of the AMO business in 2017. In 2016, Other, net includes the $947 million adjustment of the Mylan equity investment and $480 million of foreign currency exchange loss related to operations in Venezuela. Charges for restructuring actions and other cost reduction initiatives were approximately $384 million in 2017, $167 million in 2016 and $310 million in 2015. 2015 includes a $207 million pre-tax gain on the sale of a portion of the Mylan N.V. ordinary shares. |
Schedule of depreciation, additions to property, palnd and equipment and total assets by segment | Depreciation Additions to Total Assets (in millions) 2017 2016 2015 2017 2016 2015 2017 2016 2015 Established Pharmaceuticals $ $ $ $ $ $ $ $ $ Nutritionals Diagnostics Cardiovascular and Neuromodulation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Reportable Segments $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (c) Amounts exclude property, plant and equipment acquired through business acquisitions. |
Schedule of reconciliation of segment assets to total assets | 2017 2016 2015 (in millions) Total Reportable Segment Assets $ $ $ Cash and investments Non-reportable segments Goodwill and intangible assets (d) All other (d) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Assets $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (d) Goodwill and intangible assets related to AMO are included in the All other line in 2016. |
Schedule of net sales to external customers by geographic areas | Net Sales to External 2017 2016 2015 (in millions) United States $ $ $ China Germany Japan India The Netherlands Switzerland Russia France Brazil Italy United Kingdom Colombia Canada Vietnam All Other Countries ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Consolidated $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (e) Sales by country are based on the country that sold the product. |
Quarterly Results (Unaudited) (
Quarterly Results (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Quarterly Results (Unaudited) | |
Schedule of quarterly Results (Unaudited) | (in millions except per share data) 2017 2016 First Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings from Continuing Operations Basic Earnings per Common Share Diluted Earnings per Common Share Net Earnings Basic Earnings Per Common Share (a) Diluted Earnings Per Common Share (a) Market Price Per Share-High Market Price Per Share-Low Second Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings from Continuing Operations Basic Earnings per Common Share Diluted Earnings per Common Share Net Earnings Basic Earnings Per Common Share (a) Diluted Earnings Per Common Share (a) Market Price Per Share-High Market Price Per Share-Low Third Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings (Loss) from Continuing Operations ) Basic Earnings (Loss) per Common Share ) Diluted Earnings (Loss) per Common Share ) Net Earnings (Loss) ) Basic Earnings (Loss) Per Common Share (a) ) Diluted Earnings (Loss) Per Common Share (a) ) Market Price Per Share-High Market Price Per Share-Low Fourth Quarter Continuing Operations: Net Sales $ $ Gross Profit Earnings (Loss) from Continuing Operations ) Basic Earnings (Loss) per Common Share ) Diluted Earnings (Loss) per Common Share ) Net Earnings (Loss) ) Basic Earnings (Loss) Per Common Share (a) ) Diluted Earnings (Loss) Per Common Share (a) ) Market Price Per Share-High Market Price Per Share-Low (a) The sum of the four quarters of earnings per share for 2017 and 2016 may not add to the full year earnings per share amount due to rounding and/or the use of quarter-to-date weighted average shares to calculate the earnings per share amount in each respective quarter. |
Summary of Significant Accoun41
Summary of Significant Accounting Policies - Changes in Presentation (Details) | 12 Months Ended |
Dec. 31, 2017item | |
CHANGES IN PRESENTATION | |
Number of businesses disposed | 2 |
Summary of Significant Accoun42
Summary of Significant Accounting Policies - Earnings Per Share (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
EARNINGS PER SHARE | |||
Earnings from continuing operations allocated to common shares | $ 346 | $ 1,057 | $ 2,595 |
Net earnings allocated to common shares | $ 468 | $ 1,393 | $ 4,403 |
PENSION AND POST EMPLOYMENT BENEFITS | |||
Amortization period of differences between the expected long-term return on plan assets and the actual return | 5 years |
Summary of Significant Accoun43
Summary of Significant Accounting Policies - Share-Based Compensation (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
SHARE-BASED COMPENSATION | |||
Tax benefit | $ 1,878 | $ 350 | $ 577 |
Accounting Standards Update 2016-09 | |||
SHARE-BASED COMPENSATION | |||
Tax benefit | $ 120 |
Summary of Significant Accoun44
Summary of Significant Accounting Policies - Cash, Cash Equivalents And Investments (Details) $ in Millions | Dec. 31, 2017USD ($) |
CASH, CASH EQUIVALENTS AND INVESTMENTS | |
Equity method investments carrying value | $ 235 |
Summary of Significant Accoun45
Summary of Significant Accounting Policies - Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2017 | |
Buildings | Minimum | |
PROPERTY AND EQUIPMENT | |
Estimated Useful Lives | 10 years |
Buildings | Maximum | |
PROPERTY AND EQUIPMENT | |
Estimated Useful Lives | 50 years |
Buildings | Average | |
PROPERTY AND EQUIPMENT | |
Estimated Useful Lives | 27 years |
Equipment | Minimum | |
PROPERTY AND EQUIPMENT | |
Estimated Useful Lives | 3 years |
Equipment | Maximum | |
PROPERTY AND EQUIPMENT | |
Estimated Useful Lives | 20 years |
Equipment | Average | |
PROPERTY AND EQUIPMENT | |
Estimated Useful Lives | 11 years |
Discontinued Operations - By Di
Discontinued Operations - By Disposal (Details) - USD ($) shares in Thousands, $ in Millions | Feb. 27, 2015 | Feb. 10, 2015 | Apr. 30, 2015 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
After tax gain | $ 16 | $ 1,752 | |||||
Proceeds from the sale of Mylan N.V. shares | $ 2,704 | 2,290 | |||||
Gain on sale of Mylan shares | $ 45 | $ 207 | |||||
Mylan N. V. (Investee) | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
Percentage of ownership after transaction | 14.00% | ||||||
Developed markets branded generics pharmaceuticals business | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
Period of notice require to terminate manufacturing supply of products | 2 years | ||||||
Developed markets branded generics pharmaceuticals business | Minimum | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
Extension period of certain transition services | 5 months | ||||||
Period for providing manufacturing supply of products | 3 years | ||||||
Developed markets branded generics pharmaceuticals business | Maximum | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
Period of transition services | 2 years | ||||||
Extension period of certain transition services | 10 months | ||||||
Period for providing manufacturing supply of products | 10 years | ||||||
Developed markets branded generics pharmaceuticals business | Mylan N. V. (Investee) | Mylan | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
Number of ordinary shares received for sale of business | 110,000 | ||||||
Percentage of ordinary shares received for sale of business | 22.00% | ||||||
Value of ordinary shares received for sale of business | $ 5,770 | ||||||
After tax gain | $ 1,600 | ||||||
Animal Health Business | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
After tax gain | $ 130 | $ 16 | |||||
Proceeds from the disposition of business | $ 230 | $ 25 | |||||
Equity securities | Mylan N. V. (Investee) | |||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations | |||||||
Number of shares in investment sold | 40,250 | 69,750 | |||||
Proceeds from the sale of Mylan N.V. shares | $ 2,290 | $ 2,704 | |||||
Gain on sale of Mylan shares | $ 207 | $ 45 |
Discontinued Operations - Summa
Discontinued Operations - Summary (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Financial information for discontinued operations | |||
Net Sales | $ 256 | ||
Earnings (Loss) Before Tax | $ 15 | $ (4) | 13 |
Net Earnings | 124 | 321 | 65 |
Income tax benefits | 109 | 325 | 52 |
Gain on disposal of discontinued operations, net of tax | |||
After tax gain | 16 | 1,752 | |
Developed markets generics pharmaceuticals and animal health businesses | |||
Financial information for discontinued operations | |||
Net Sales | 256 | ||
Earnings (Loss) Before Tax | 15 | (4) | 13 |
Net Earnings | 15 | 3 | 62 |
Gain on disposal of discontinued operations, net of tax | |||
Pretax gain | 2,840 | ||
Tax expenses from discontinued operations | 1,088 | ||
After tax gain | 1,752 | ||
Developed markets branded generics pharmaceuticals businesses | |||
Gain on disposal of discontinued operations, net of tax | |||
Tax expenses from discontinued operations | 667 | ||
AbbVie | |||
Financial information for discontinued operations | |||
Net Earnings | $ 109 | $ 318 | 3 |
Tax benefit related to the resolution of various tax positions related to prior years | $ 48 |
Assets and Liabilities Held f48
Assets and Liabilities Held for Disposition - General (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | ||
Feb. 28, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Assets and liabilities held for disposition | ||||
Earnings (losses) before taxes | $ 2,231 | $ 1,413 | $ 3,183 | |
Disclosures | ||||
After tax gain | 16 | 1,752 | ||
AMO | Dispositions held for sale | ||||
Assets and liabilities held for disposition | ||||
Sale consideration | 4,325 | |||
Earnings (losses) before taxes | (18) | $ 30 | $ 64 | |
Disclosures | ||||
After tax gain | 728 | |||
AMO | Dispositions held for sale | Other (income) expense, net | ||||
Disclosures | ||||
Pre-tax gain on sale of disposal group | $ 1,163 | $ 1,163 |
Assets and Liabilities Held f49
Assets and Liabilities Held for Disposition - Summary of Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 |
Disposals as part of acquisitions | ||
Current assets held for disposition | $ 20 | $ 513 |
Current liabilities held for disposition | 245 | |
Dispositions held for sale | AMO | ||
Disposals as part of acquisitions | ||
Trade receivables, net | 12 | 222 |
Total inventories | 8 | 240 |
Prepaid expenses and other current assets | 51 | |
Current assets held for disposition | 20 | 513 |
Net property and equipment | 56 | 247 |
Intangible assets, net of amortization | 18 | 529 |
Goodwill | 102 | 1,966 |
Deferred income taxes and other assets | 11 | |
Non-current assets held for disposition | 176 | 2,753 |
Total assets held for disposition | $ 196 | 3,266 |
Trade accounts payable | 71 | |
Salaries, wages, commissions and other accrued liabilities | 174 | |
Current liabilities held for disposition | 245 | |
Post-employment obligations, deferred income taxes and other long-term liabilities | 59 | |
Total liabilities held for disposition | $ 304 |
Supplemental Financial Inform50
Supplemental Financial Information - Other income and expense (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | |||
Feb. 28, 2017 | Apr. 30, 2015 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Supplemental financial information | |||||
Mylan N.V. equity investment adjustment | $ 947 | ||||
Gain on sale of Mylan shares | $ 45 | $ 207 | |||
Other (income) expense, net | |||||
Supplemental financial information | |||||
Increase (decrease) in fair value of contingent consideration liability related to a business acquisition | $ (79) | ||||
Other (income) expense, net | Mylan N. V. (Investee) | |||||
Supplemental financial information | |||||
Mylan N.V. equity investment adjustment | $ 947 | ||||
Gain on sale of Mylan shares | $ 207 | 45 | |||
AMO | Dispositions held for sale | Other (income) expense, net | |||||
Supplemental financial information | |||||
Pre-tax gain on sale of disposal group | $ 1,163 | $ 1,163 |
Supplemental Financial Inform51
Supplemental Financial Information - Investments (Details) - USD ($) shares in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended | ||
Apr. 30, 2015 | Dec. 31, 2017 | Dec. 31, 2015 | Dec. 31, 2016 | |
Investments | ||||
Long-term Investments | $ 883 | $ 2,947 | ||
Proceeds from the sale of Mylan N.V. shares | 2,704 | $ 2,290 | ||
Gain on sale of Mylan shares | 45 | $ 207 | ||
Mylan N. V. (Investee) | Other (income) expense, net | ||||
Investments | ||||
Gain on sale of Mylan shares | $ 207 | 45 | ||
Equity securities | ||||
Investments | ||||
Long-term Investments | 797 | 2,906 | ||
Equity securities | St Jude Medical | ||||
Investments | ||||
Securities in mutual funds held in a rabbi trust | 363 | |||
Equity securities | Mylan N. V. (Investee) | ||||
Investments | ||||
Proceeds from the sale of Mylan N.V. shares | $ 2,290 | $ 2,704 | ||
Number of shares in investment sold | 40,250 | 69,750 | ||
Carrying value of investment at the time of sale | $ 2,700 | |||
Gain on sale of Mylan shares | $ 207 | 45 | ||
Other | ||||
Investments | ||||
Long-term Investments | $ 86 | $ 41 |
Supplemental Financial Inform52
Supplemental Financial Information - Other accrued liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 |
Other Accrued Liabilities: | ||
Accrued rebates payable to government agencies | $ 124 | $ 110 |
Accrued other rebates | 498 | 296 |
All other | 3,189 | 2,175 |
Total | 3,811 | 2,581 |
Accrued wholesaler chargeback rebates | $ 178 | $ 214 |
Supplemental Financial Inform53
Supplemental Financial Information - Post-employment obligations and other long-term liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Post-employment Obligations and Other Long-term Liabilities: | |||
Defined benefit pension plans and post-employment medical and dental plans for significant plans | $ 2,169 | $ 2,154 | |
Deferred income taxes | 2,006 | 356 | |
All other | 4,855 | 2,039 | |
Total | 9,030 | 4,549 | |
All other disclosures | |||
Net unrecognized tax benefits from acquisition | 1,440 | 972 | $ 1,438 |
Post-employment Obligations and Other Long-term Liabilities: | |||
All other disclosures | |||
Net unrecognized tax benefits from acquisition | 835 | 560 | |
Acquisition contingent consideration, noncurrent | $ 100 | $ 130 |
Supplemental Financial Inform54
Supplemental Financial Information - Foreign currency (Details) $ in Millions | 12 Months Ended | ||||
Dec. 31, 2016USD ($) | Mar. 31, 2016 | Feb. 17, 2016 | Feb. 16, 2016 | Dec. 31, 2015 | |
Foreign currency disclosures | |||||
Foreign currency exchange loss on remeasurement | $ 480 | ||||
Venezuela | |||||
Foreign currency disclosures | |||||
Foreign currency exchange loss on remeasurement | $ 480 | ||||
CENCOEX | |||||
Foreign currency disclosures | |||||
Official rate to U.S. dollar | 6.3 | ||||
SICAD | |||||
Foreign currency disclosures | |||||
Official rate to U.S. dollar | 13.5 | ||||
SIMADI | |||||
Foreign currency disclosures | |||||
Official rate to U.S. dollar | 200 | ||||
DIPRO | |||||
Foreign currency disclosures | |||||
Official rate to U.S. dollar | 10 | 6.3 | |||
DICOM | |||||
Foreign currency disclosures | |||||
Official rate to U.S. dollar | 263 | ||||
Venezuelan bolivars | |||||
Foreign currency disclosures | |||||
Official rate to U.S. dollar | 6.3 |
Accumulated Other Comprehensi55
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Other comprehensive income (loss) from continuing operations, net of income taxes | |||
Beginning of Year | $ 20,538 | ||
Other Comprehensive Income (Loss) | 1,052 | $ (605) | $ (1,732) |
End of Year | 30,897 | 20,538 | |
Accumulated Other Comprehensive Income (Loss): | |||
Other comprehensive income (loss) from continuing operations, net of income taxes | |||
Beginning of Year | (7,263) | (6,658) | |
Impact of business dispositions | 149 | 127 | |
Other comprehensive income (loss) before reclassifications | 1,044 | (1,591) | |
(Income) loss amounts reclassified from accumulated other comprehensive income | 8 | 986 | |
Other Comprehensive Income (Loss) | 1,052 | (605) | (1,732) |
End of Year | (6,062) | (7,263) | (6,658) |
Cumulative Foreign Currency Translation Adjustments | |||
Other comprehensive income (loss) from continuing operations, net of income taxes | |||
Beginning of Year | (4,959) | (4,829) | |
Impact of business dispositions | 142 | ||
Other comprehensive income (loss) before reclassifications | 1,365 | (130) | |
Other Comprehensive Income (Loss) | 1,365 | (130) | |
End of Year | (3,452) | (4,959) | (4,829) |
Net Actuarial Losses and Prior Service Costs and Credits | |||
Other comprehensive income (loss) from continuing operations, net of income taxes | |||
Beginning of Year | (2,284) | (1,958) | |
Impact of business dispositions | 6 | ||
Other comprehensive income (loss) before reclassifications | (333) | (393) | |
(Income) loss amounts reclassified from accumulated other comprehensive income | 90 | 67 | |
Other Comprehensive Income (Loss) | (243) | (326) | |
End of Year | (2,521) | (2,284) | (1,958) |
Cumulative Unrealized Gains (Losses) on Marketable Equity Securities | |||
Other comprehensive income (loss) from continuing operations, net of income taxes | |||
Beginning of Year | (69) | 65 | |
Other comprehensive income (loss) before reclassifications | 182 | (1,109) | |
(Income) loss amounts reclassified from accumulated other comprehensive income | (118) | 975 | |
Other Comprehensive Income (Loss) | 64 | (134) | |
End of Year | (5) | (69) | 65 |
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges | |||
Other comprehensive income (loss) from continuing operations, net of income taxes | |||
Beginning of Year | 49 | 64 | |
Impact of business dispositions | 1 | ||
Other comprehensive income (loss) before reclassifications | (170) | 41 | |
(Income) loss amounts reclassified from accumulated other comprehensive income | 36 | (56) | |
Other Comprehensive Income (Loss) | (134) | (15) | |
End of Year | $ (84) | $ 49 | $ 64 |
Business Acquisitions - St. Jud
Business Acquisitions - St. Jude (Details) - USD ($) $ / shares in Units, $ in Millions | Jan. 20, 2017 | Jan. 04, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Allocation of the fair value | |||||
Goodwill, non-deductible | $ 24,020 | $ 7,683 | |||
Disposals as part of acquisitions | |||||
Gain or loss on sale | $ 1,163 | 25 | $ 2,840 | ||
St Jude Medical | |||||
Business acquisitions | |||||
Total consideration for business acquisition | $ 23,600 | ||||
Cash paid for business acquisition | 13,600 | ||||
Issue of equity for business acquisition | $ 10,000 | ||||
Number of equity shares issued for business acquisition | 254,000,000 | ||||
Debt assumed and subsequently repaid or refinanced | $ 5,900 | ||||
Share price of shares received in acquisition per agreement (in dollars per share) | $ 46.75 | ||||
Share received (in shares) | 0.8708 | ||||
Stock price (in dollars per share) | $ 39.36 | ||||
Expected value per common share (in dollars per share) | $ 81 | ||||
Allocation of the fair value | |||||
Acquired intangible assets, non-deductible | $ 15,500 | ||||
Goodwill, non-deductible | 13,100 | ||||
Acquired net tangible assets | 3,000 | ||||
Deferred income taxes recorded at acquisition | (2,700) | ||||
Net debt | (5,300) | ||||
Total final allocation of fair value | 23,600 | ||||
Trade accounts receivable | 1,100 | ||||
Inventory | 1,700 | ||||
Other current assets | 176 | ||||
Property and equipment | 1,500 | ||||
Other long-term assets | 455 | ||||
Trade accounts payable and other current liabilities | 1,100 | ||||
Other non-current liabilities | 870 | ||||
St Jude Medical | 120-day senior unsecured bridge term loan | |||||
Business acquisitions | |||||
Proceeds from bridge loan | $ 2,000 | ||||
Maturity period | 120 days | ||||
St. Jude Medical Angio-Seal and Femoseal vascular closure and Abbott's Vado Steerable Sheath businesses | Disposal Group, Disposed of by Sale, Not Discontinued Operations | |||||
Disposals as part of acquisitions | |||||
Proceeds from sale of businesses | $ 1,120 | ||||
Gain or loss on sale | $ 0 |
Business Acquisitions - Alere I
Business Acquisitions - Alere Inc. (Details) $ / shares in Units, $ in Millions | Oct. 03, 2017USD ($)$ / shares | Sep. 30, 2017USD ($)installment | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) |
Allocation of the fair value | |||||
Goodwill, non-deductible | $ 24,020 | $ 7,683 | |||
Disposals as part of acquisitions | |||||
Gain or loss on sale | 1,163 | $ 25 | $ 2,840 | ||
Alere Inc | |||||
Business acquisitions | |||||
Share price of shares received in acquisition per agreement (in dollars per share) | $ / shares | $ 51 | ||||
Issue of equity for business acquisition | $ 4,500 | ||||
Debt assumed and subsequently repaid or refinanced | 3,000 | ||||
Allocation of the fair value | |||||
Acquired intangible assets, non-deductible | 3,500 | ||||
Goodwill, non-deductible | 4,100 | ||||
Acquired net tangible assets | 900 | ||||
Deferred income taxes recorded at acquisition | (700) | ||||
Net debt | (2,600) | ||||
Preferred stock | (700) | ||||
Total preliminary allocation of fair value | 4,500 | ||||
Trade accounts receivable | 430 | ||||
Inventory | 425 | ||||
Other current assets | 206 | ||||
Property and equipment | 540 | ||||
Other long-term assets | 112 | ||||
Trade accounts payable and other current liabilities | 625 | ||||
Other non-current liabilities | $ 160 | ||||
Disposal Group, held for disposition | Alere Inc | |||||
Disposals as part of acquisitions | |||||
Gain or loss on sale | $ 0 | ||||
Triage MeterPro Business | Disposal Group, held for disposition | Alere Inc | |||||
Disposals as part of acquisitions | |||||
Sale consideration | $ 400 | ||||
Sale consideration receivable in annual installments | $ 240 | ||||
Number of installments | installment | 6 | ||||
Triage MeterPro Business | Disposal Group, held for disposition | Alere Inc | Maximum | |||||
Disposals as part of acquisitions | |||||
Contingent consideration asset | $ 40 | ||||
Epocal Inc. | Disposal Group, held for disposition | Alere Inc | |||||
Disposals as part of acquisitions | |||||
Sale consideration | $ 200 |
Business Acquisitions - Revenue
Business Acquisitions - Revenue and Earnings (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Consolidated Statement of Earnings | |||||||||||
Net Sales | $ 7,589 | $ 6,829 | $ 6,637 | $ 6,335 | $ 5,333 | $ 5,302 | $ 5,333 | $ 4,885 | $ 27,390 | $ 20,853 | $ 20,405 |
Pre-tax loss | 2,231 | 1,413 | 3,183 | ||||||||
Amortization of intangible assets | 1,975 | 550 | $ 601 | ||||||||
Amortization of inventory step-up | 907 | ||||||||||
St Jude Medical Inc and Alere Inc. | |||||||||||
Consolidated Statement of Earnings | |||||||||||
Net Sales | 6,500 | ||||||||||
Pre-tax loss | (1,300) | ||||||||||
Amortization of intangible assets | 1,500 | ||||||||||
Amortization of inventory step-up | 907 | ||||||||||
Pro forma financial information | |||||||||||
Pro forma consolidated net sales | 28,900 | 28,900 | |||||||||
Pro forma consolidated net earnings (loss) | 750 | (485) | |||||||||
Amortization of inventory step-up | 940 | ||||||||||
Amortization of intangibles | $ 225 | $ 1,700 |
Business Acquisitions - Alere P
Business Acquisitions - Alere Preferred Stock Tender Offer (Details) - Convertible Perpetual Preferred Stock, Series B - Alere Inc - $ / shares shares in Thousands | Oct. 03, 2017 | Jul. 17, 2017 | Dec. 31, 2017 |
Acquisitions - other disclosures | |||
Number of shares of stock to be acquired for cash per a tender offer (in shares) | 1,770 | ||
Price of shares to be acquired for cash per a tender offer (n dollars per share) | $ 402 | ||
Number of shares accepted for payment per tender offer (in shares) | 1,748 | ||
Remaining liquidation preference share (in dollars per share) | $ 400 |
Business Acquisitions - Tendyne
Business Acquisitions - Tendyne Holdings (Details) - USD ($) $ in Millions | 1 Months Ended | ||
Aug. 31, 2015 | Dec. 31, 2017 | Dec. 31, 2016 | |
Allocation of the fair value | |||
Goodwill, non-deductible | $ 24,020 | $ 7,683 | |
Tendyne Holdings, Inc. | |||
Business acquisitions | |||
Cash paid for business acquisition | $ 225 | ||
Additional payments upon completion of certain regulatory milestones | 150 | ||
Allocation of the fair value | |||
Non-deductible acquired in-process research and development | 220 | ||
Goodwill, non-deductible | 142 | ||
Deferred tax assets and other net assets | 18 | ||
Deferred tax liabilities | 85 | ||
Contingent consideration | $ 70 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Goodwill and intangible assets information | ||
Goodwill | $ 24,020 | $ 7,683 |
Goodwill acquired | 79 | |
Change in goodwill due to foreign currency translation adjustments | 653 | $ (66) |
Established Pharmaceutical Products | ||
Goodwill and intangible assets information | ||
Goodwill | 3,200 | |
Nutritional Products | ||
Goodwill and intangible assets information | ||
Goodwill | 286 | |
Diagnostic Products | ||
Goodwill and intangible assets information | ||
Goodwill | 4,100 | |
Cardiovascular and Neuromodulation Products | ||
Goodwill and intangible assets information | ||
Goodwill | 15,500 | |
AMO | Dispositions held for sale | ||
Goodwill and intangible assets information | ||
Goodwill reclassified to non-current assets held for disposition | 2,000 | |
St Jude Medical Inc and Alere Inc. | ||
Goodwill and intangible assets information | ||
Goodwill acquired | 17,200 | |
Terumo, Quidel and Siemens | St Jude Medical Inc and Alere Inc. | ||
Goodwill and intangible assets information | ||
Decrease in goodwill due to sale of certain businessess | $ 1,500 |
Goodwill and Intangible Asset62
Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Goodwill and Intangible Assets | ||
Gross amount of amortizable intangible assets | $ 25,600 | $ 10,400 |
Accumulated amortization of intangible assets | 8,100 | 6,200 |
Amortizable intangible assets acquired | 104 | |
Increase in intangible assets due to foreign currency translation adjustment | 227 | 6 |
Indefinite-lived intangible assets related to in-process research and development acquired in a business combination | 3,900 | 349 |
Estimated annual amortization expense, intangible assets, 2018 | 2,400 | |
Estimated annual amortization expense, intangible assets, 2019 | 2,300 | |
Estimated annual amortization expense, intangible assets, 2020 | 2,100 | |
Estimated annual amortization expense, intangible assets, 2021 | 2,000 | |
Estimated annual amortization expense, intangible assets, 2022 | 2,000 | |
Non-reportable segment | ||
Goodwill and Intangible Assets | ||
Impairment of indefinite-lived intangible assets in-process research and development project | $ 59 | |
Cardiovascular and Neuromodulation Products segment | ||
Goodwill and Intangible Assets | ||
Impairment of indefinite-lived intangible assets in-process research and development project | $ 53 | |
Minimum | ||
Goodwill and Intangible Assets | ||
Amortization period of intangible assets | 2 years | |
Maximum | ||
Goodwill and Intangible Assets | ||
Amortization period of intangible assets | 20 years | |
Average | ||
Goodwill and Intangible Assets | ||
Amortization period of intangible assets | 14 years | |
St Jude Medical Inc and Alere Inc. | ||
Goodwill and Intangible Assets | ||
Amortizable intangible assets acquired | $ 14,500 | |
Indefinite-lived intangible assets acquired | 4,500 | |
St Jude Medical Inc and Alere Inc. | Quidel and Siemens | ||
Goodwill and Intangible Assets | ||
Decrease in intangible assets due to sale of certain businesses | 210 | |
Dispositions held for sale | AMO | ||
Goodwill and Intangible Assets | ||
Net intangible assets moved to Non-current assets held for disposition | $ 529 |
Restructuring Plans (Details)
Restructuring Plans (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Restructuring Plan 2017 | ||||
Restructuring costs | ||||
Liabilities assumed as part of business acquisition | $ 23 | |||
Restructuring charges | 187 | |||
Payments and other adjustments | (142) | |||
Accrued balance | 68 | |||
Restructuring Plan 2017 | Cost of products sold | ||||
Restructuring costs | ||||
Restructuring charges | 5 | |||
Restructuring Plan 2017 | Selling, general and administrative expense | ||||
Restructuring costs | ||||
Restructuring charges | 182 | |||
Restructuring Plan from 2014 to 2017 | ||||
Restructuring costs | ||||
Restructuring charges | 120 | $ 33 | $ 95 | $ 164 |
Payments and other adjustments | (45) | (67) | (113) | (46) |
Accrued balance | 141 | 66 | 100 | $ 118 |
Employee related severance and other charges | 120 | 33 | 95 | |
Additional charges for accelerated depreciation | 2 | 2 | 45 | |
Restructuring Plan from 2014 to 2017 | Cost of products sold | ||||
Restructuring costs | ||||
Restructuring charges | 7 | 9 | 18 | |
Restructuring Plan from 2014 to 2017 | Research and development | ||||
Restructuring costs | ||||
Restructuring charges | 77 | 5 | 34 | |
Restructuring Plan from 2014 to 2017 | Selling, general and administrative expense | ||||
Restructuring costs | ||||
Restructuring charges | $ 36 | $ 19 | $ 43 |
Restructuring Plans - Restructu
Restructuring Plans - Restructuring Activity (Details) - Restructuring Plan from 2014 to 2017 - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Restructuring reserve activity | ||||
Accrued balance at beginning of year | $ 66 | $ 100 | $ 118 | |
Restructuring charges | 120 | 33 | 95 | $ 164 |
Payments and other adjustments | (45) | (67) | (113) | (46) |
Accrued balance at end of year | $ 141 | $ 66 | $ 100 | $ 118 |
Incentive Stock Program - Gener
Incentive Stock Program - General (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2017 | Apr. 30, 2017 | Dec. 31, 2016 | |
2017 Incentive Stock Program | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Incentive stock programs, shares authorized for issuance | 170,000,000 | ||
Incentive stock programs, shares reserved for future issuance | 169,000,000 | ||
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Stock options outstanding, weighted-average exercise price (in dollars per share) | $ 36.85 | $ 34.17 | |
Stock options granted during the period (in shares) | 4,985,970 | ||
Award vesting period | 3 years | ||
Stock options | St Jude Medical | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Number of awards converted as part of acquisition (in shares) | 7,364,571 | ||
Stock options outstanding, weighted-average exercise price (in dollars per share) | $ 30.50 | ||
Stock options | 2017 Incentive Stock Program | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Stock options granted during the period (in shares) | 4,985,970 | ||
Stock options | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Maximum term of option | 10 years | ||
Restricted stock awards | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Portion of awards vesting in any one year for awards that vest over 5 years (as a percent) | 33.00% | ||
For awards with a term of five years, number of years in which no more than one-third of the award vests | 1 year | ||
Restricted stock awards | 2017 Incentive Stock Program | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Grants in period, restricted stock (in shares) | 580,203 | ||
Restricted stock awards | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Award vesting period | 3 years | ||
Restricted stock awards | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Award vesting period | 5 years | ||
Restricted stock units | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Award vesting period | 3 years | ||
Number of shares of common stock received for each vested restricted stock unit (in shares) | 1 | ||
Restricted stock units | St Jude Medical | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Number of awards converted as part of acquisition (in shares) | 2,324,500 | ||
Awards and units outstanding, weighted-average grant-date fair value (in dollars per share) | $ 37.69 | ||
Restricted stock units | 2017 Incentive Stock Program | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Awards and units granted during period (in shares) | 7,687,009 |
Incentive Stock Program - Restr
Incentive Stock Program - Restricted Awards and Units (Details) - Restricted stock awards and restricted stock units - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award | |||
Awards and units outstanding (in shares) | 15,518,719 | 13,705,511 | |
Awards and units outstanding, weighted-average grant-date fair value (in dollars per share) | $ 42.82 | $ 41.03 | |
Awards and units granted during period (in shares) | 8,267,212 | ||
Awards and units granted during period, weighted-average grant-date fair value (in dollars per share) | $ 45.20 | ||
Awards and units converted during period (in shares) | 2,324,500 | ||
Awards and units converted during period, weighted-average grant-date fair value (in dollars per share) | $ 37.69 | ||
Awards and units vested during period (in shares) | 7,553,969 | ||
Awards and units vested during period, weighted-average grant-date fair value (in dollars per share) | $ 40.77 | ||
Awards and units lapsed during period (in shares) | 1,224,535 | ||
Awards and units lapsed during period, weighted-average grant-date fair value (in dollars per share) | $ 41.76 | ||
Fair value of awards and units vested | $ 348 | $ 225 | $ 312 |
Incentive Stock Program - Optio
Incentive Stock Program - Options Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Stock Options Outstanding During The Period | |||
Stock options outstanding at the beginning of the period (in shares) | 35,888,333 | ||
Stock options granted during the period (in shares) | 4,985,970 | ||
Stock options Converted for St. Jude Medical during the period (in shares) | 7,364,571 | ||
Stock options exercised during the period (in shares) | (11,620,026) | ||
Stock options lapsed during the period (in shares) | (805,048) | ||
Stock options outstanding at the end of the period (in shares) | 35,813,800 | 35,888,333 | |
Exercisable options outstanding at the beginning of the period (in shares) | 23,290,260 | ||
Exercisable options outstanding at the end of the period (in shares) | 22,216,890 | 23,290,260 | |
Stock Options Weighted Average Exercise Price | |||
Stock options outstanding at the beginning of the period, weighted-average exercise price (in dollars per share) | $ 34.17 | ||
Stock options granted during the period, weighted-average exercise price (in dollars per share) | 45.03 | ||
Stock options converted for St. Jude Medical during the period, weighted-average exercise price (in dollars per share) | 30.50 | ||
Stock options exercised during the period, weighted-average exercise price (in dollars per share) | 27.85 | ||
Stock options lapsed during the period, weighted-average exercise price (in dollars per share) | 39.76 | ||
Stock options outstanding at the end of the period, weighted-average exercise price (in dollars per share) | 36.85 | $ 34.17 | |
Exercisable options outstanding, weighted-average exercise price at the beginning of the period (in dollars per share) | 30.48 | ||
Exercisable options outstanding, weighted-average exercise price at the end of the period (in dollars per share) | $ 34.54 | $ 30.48 | |
Stock Options Weighted Average Remaining Life (Years) | |||
Stock options outstanding, weighted-average remaining life | 5 years 9 months 18 days | 5 years 3 months 18 days | |
Exercisable options, weighted-average remaining life | 4 years 8 months 12 days | 3 years 6 months | |
Aggregate intrinsic value of options outstanding | $ 500 | ||
Aggregate intrinsic value of options exercisable | 500 | ||
Total intrinsic value of options exercised | 233 | $ 98 | $ 167 |
Total unrecognized compensation cost | $ 291 | ||
Total unrecognized compensation cost, recognition period | 3 years |
Incentive Stock Program - Expen
Incentive Stock Program - Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Accounting Standards Update 2016-09 | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Tax benefit recognized in total non-cash compensation expense | $ 120 | ||
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||
Total non-cash compensation expense charged against income | 406 | $ 310 | $ 291 |
Tax benefit recognized in total non-cash compensation expense | $ 242 | $ 100 | $ 98 |
Incentive Stock Program - Opt69
Incentive Stock Program - Options Fair Value (Details) - Stock options - $ / shares | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award | |||
Fair value of an option granted (in dollars per share) | $ 6.54 | $ 4.38 | $ 6.67 |
Fair value assumptions: | |||
Risk-free interest rate (as a percent) | 2.10% | 1.40% | 1.80% |
Average life of options (years) | 6 years | 6 years | 6 years |
Volatility (as a percent) | 18.00% | 17.00% | 17.00% |
Dividend yield (as a percent) | 2.40% | 2.70% | 2.00% |
Debt and Lines of Credit - Sche
Debt and Lines of Credit - Schedule (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Jun. 30, 2017 | Dec. 31, 2016 |
Debt Instrument | |||
Unamortized debt issuance costs | $ (119) | $ (117) | |
Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges | (121) | (102) | |
Total, net of current maturities | 27,210 | 20,681 | |
Current maturities of long-term debt | 508 | 3 | |
Total carrying amount | 27,718 | 20,684 | |
5.125% Notes, due 2019 | |||
Debt Instrument | |||
Total, net of current maturities | $ 947 | $ 947 | |
Interest rate percentage | 5.125% | 5.125% | |
2.35% Notes, due 2019 | |||
Debt Instrument | |||
Total, net of current maturities | $ 2,850 | $ 2,850 | |
Interest rate percentage | 2.35% | 2.35% | |
2.50% Line of credit borrowing due 2019 | |||
Debt Instrument | |||
Total, net of current maturities | $ 1,150 | ||
Interest rate percentage | 2.50% | ||
2.80% Notes, due 2020 | |||
Debt Instrument | |||
Total, net of current maturities | $ 500 | ||
Interest rate percentage | 2.80% | ||
4.125% Notes, due 2020 | |||
Debt Instrument | |||
Total, net of current maturities | $ 597 | $ 597 | |
Interest rate percentage | 4.125% | 4.125% | |
2.00% Notes, due 2020 | |||
Debt Instrument | |||
Total, net of current maturities | $ 750 | $ 750 | |
Interest rate percentage | 2.00% | 2.00% | 2.00% |
2.90% Notes, due 2021 | |||
Debt Instrument | |||
Total, net of current maturities | $ 2,850 | $ 2,850 | |
Interest rate percentage | 2.90% | 2.90% | |
2.55% Notes, due 2022 | |||
Debt Instrument | |||
Total, net of current maturities | $ 750 | $ 750 | |
Interest rate percentage | 2.55% | 2.55% | 2.55% |
2.62% Term loan due 2022 | |||
Debt Instrument | |||
Total, net of current maturities | $ 2,800 | ||
Interest rate percentage | 2.62% | ||
3.25% Notes, due 2023 | |||
Debt Instrument | |||
Total, net of current maturities | $ 900 | ||
Interest rate percentage | 3.25% | ||
3.40% Notes, due 2023 | |||
Debt Instrument | |||
Total, net of current maturities | $ 1,500 | $ 1,500 | |
Interest rate percentage | 3.40% | 3.40% | |
3.875% Notes, due 2025 | |||
Debt Instrument | |||
Total, net of current maturities | $ 500 | ||
Interest rate percentage | 3.875% | ||
2.95% Notes, due 2025 | |||
Debt Instrument | |||
Total, net of current maturities | $ 1,000 | $ 1,000 | |
Interest rate percentage | 2.95% | 2.95% | |
3.75% Notes, due 2026 | |||
Debt Instrument | |||
Total, net of current maturities | $ 3,000 | $ 3,000 | |
Interest rate percentage | 3.75% | 3.75% | |
4.75% Notes, due 2036 | |||
Debt Instrument | |||
Total, net of current maturities | $ 1,650 | $ 1,650 | |
Interest rate percentage | 4.75% | 4.75% | |
6.15% Notes, due 2037 | |||
Debt Instrument | |||
Total, net of current maturities | $ 547 | $ 547 | |
Interest rate percentage | 6.15% | 6.15% | |
6.0% Notes, due 2039 | |||
Debt Instrument | |||
Total, net of current maturities | $ 515 | $ 515 | |
Interest rate percentage | 6.00% | 6.00% | |
5.3% Notes, due 2040 | |||
Debt Instrument | |||
Total, net of current maturities | $ 694 | $ 694 | |
Interest rate percentage | 5.30% | 5.30% | |
4.75% Notes, due 2043 | |||
Debt Instrument | |||
Total, net of current maturities | $ 700 | ||
Interest rate percentage | 4.75% | ||
4.90% Notes, due 2046 | |||
Debt Instrument | |||
Total, net of current maturities | $ 3,250 | $ 3,250 | |
Interest rate percentage | 4.90% | 4.90% |
Debt and Lines of Credit - St.
Debt and Lines of Credit - St. Jude (Details) $ in Millions | 3 Months Ended | ||||
Mar. 31, 2017USD ($)NotesSeries | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Nov. 30, 2016USD ($) | Mar. 31, 2015USD ($) | |
Debt Instrument | |||||
Debt issued - principal amount | $ 15,100 | $ 2,500 | |||
Debt outstanding | $ 27,718 | $ 20,684 | |||
St Jude Medical | |||||
Debt Instrument | |||||
Repayments of debt | $ 2,800 | ||||
Senior Notes | |||||
Debt Instrument | |||||
Debt issued - principal amount | 2,900 | ||||
Senior Notes | St Jude Medical | |||||
Debt Instrument | |||||
Debt outstanding | $ 194.2 | ||||
Number of series of existing notes | NotesSeries | 5 | ||||
2.00% Senior Notes due 2018 | |||||
Debt Instrument | |||||
Debt issued - principal amount | $ 473.8 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | ||||
2.80% Senior Notes due 2020 | |||||
Debt Instrument | |||||
Debt issued - principal amount | $ 483.7 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 2.80% | ||||
3.25% Senior Notes due 2023 | |||||
Debt Instrument | |||||
Debt issued - principal amount | $ 818.4 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 3.25% | ||||
3.875% Senior Notes due 2025 | |||||
Debt Instrument | |||||
Debt issued - principal amount | $ 490.7 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | ||||
4.75% Senior Notes due 2043 | |||||
Debt Instrument | |||||
Debt issued - principal amount | $ 639.1 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 4.75% |
Debt and Lines of Credit - Loan
Debt and Lines of Credit - Loan Facility (Details) - USD ($) $ in Millions | Oct. 03, 2017 | Oct. 02, 2017 | Jul. 31, 2017 | Jan. 04, 2017 | Mar. 31, 2017 | Dec. 31, 2017 | Mar. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2016 |
Debt Instrument | |||||||||
Short-term debt outstanding | $ 206 | $ 206 | $ 1,322 | ||||||
2014 revolving credit agreement | |||||||||
Debt Instrument | |||||||||
Repayments of debt | 550 | ||||||||
Maximum borrowing capacity | 5,000 | $ 5,000 | |||||||
Proceeds from line of credit | $ 1,700 | $ 0 | |||||||
St Jude Medical | |||||||||
Debt Instrument | |||||||||
Repayments of debt | $ 2,800 | ||||||||
Alere Inc | |||||||||
Debt Instrument | |||||||||
Proceeds from bridge loan | $ 2,800 | ||||||||
Maturity period | 5 years | ||||||||
Repayments of debt | 3,000 | ||||||||
Maximum borrowing capacity | $ 2,800 | ||||||||
120-day senior unsecured bridge term loan | St Jude Medical | |||||||||
Debt Instrument | |||||||||
Proceeds from bridge loan | $ 2,000 | ||||||||
Maturity period | 120 days | ||||||||
Repayments of debt | $ 2,000 | ||||||||
364-day yen-denominated debt | |||||||||
Debt Instrument | |||||||||
Maturity period | 364 days | ||||||||
Short-term debt outstanding | $ 195 | $ 195 | |||||||
Yen-denominated short-term debt | |||||||||
Debt Instrument | |||||||||
Debt paid off | $ 479 | $ 479 |
Debt and Lines of Credit - Seni
Debt and Lines of Credit - Senior Notes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Nov. 30, 2016 | Mar. 31, 2015 | |
Debt Instrument | |||
Debt issued - principal amount | $ 15,100 | $ 2,500 | |
2.35% Senior Notes, due 2019 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 2,850 | ||
Interest rate percentage | 2.35% | ||
2.90% Senior Notes, due 2021 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 2,850 | ||
Interest rate percentage | 2.90% | ||
3.40% Senior Notes, due 2023 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 1,500 | ||
Interest rate percentage | 3.40% | ||
3.75% Senior Notes, due 2026 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 3,000 | ||
Interest rate percentage | 3.75% | ||
4.75% Senior Notes, due 2036 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 1,650 | ||
Interest rate percentage | 4.75% | ||
4.90% Senior Notes, due 2046 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 3,250 | ||
Interest rate percentage | 4.90% | ||
Interest rate swaps | |||
Debt Instrument | |||
Notional amount of contracts entered during the period | $ 3,000 | 2,500 | |
Notional amount of unwound contracts entered during the period | $ 1,500 | ||
2.00% Senior Notes due March 15, 2020 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 750 | ||
Interest rate percentage | 2.00% | ||
2.55% Senior Notes due March 15, 2022 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 750 | ||
Interest rate percentage | 2.55% | ||
2.95% Senior Notes due March 15, 2025 | |||
Debt Instrument | |||
Debt issued - principal amount | $ 1,000 | ||
Interest rate percentage | 2.95% |
Debt and Lines of Credit - Prin
Debt and Lines of Credit - Principal Payments (Details) $ in Millions | Dec. 31, 2017USD ($) |
Principal payments of long-term debt | |
Principal payments required in 2018 | $ 508 |
Principal payments required in 2019 | 5,000 |
Principal payments required in 2020 | 1,800 |
Principal payments required in 2021 | 2,900 |
Principal payments required in 2022 | 3,600 |
Principal payments required in 2023 and thereafter | $ 14,300 |
Debt and Lines of Credit - Avai
Debt and Lines of Credit - Available Credit and Commitment (Details) - USD ($) $ in Billions | Jan. 29, 2017 | Feb. 29, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Debt Instrument | |||||
Unused lines of credit | $ 5 | ||||
Weighted-average interest rate on short-term borrowings | 0.30% | 0.60% | 0.20% | ||
364-day senior unsecured bridge term loan facility | Unfunded Loan Commitment | |||||
Debt Instrument | |||||
Maturity period | 364 days | ||||
Maximum borrowing capacity | $ 9 | ||||
Maximum extension period available automatically | 90 days |
Financial Instruments, Deriva76
Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | ||||
Mar. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Jun. 30, 2017 | |
Derivative instruments, notional amount and fair value | ||||||
Fair Value - Liabilities | $ 610 | $ 298 | $ 610 | |||
Gross unrealized holding gains (losses) on available-for-sale equity securities | $ 10 | (5) | $ 10 | $ 171 | ||
Yen-denominated short-term debt | ||||||
Derivative instruments, notional amount and fair value | ||||||
Repayment of short-term debt designated as a hedge of the net investment in a foreign subsidiary | $ 479 | $ 479 | ||||
Interest rate swap to 2.00% and 2.55% notes | ||||||
Derivative instruments, notional amount and fair value | ||||||
Unwounded interest rate swaps | $ 1,500 | |||||
2.00% Notes, due 2020 | ||||||
Derivative instruments, notional amount and fair value | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | 2.00% | 2.00% | 2.00% | ||
2.55% Notes, due 2022 | ||||||
Derivative instruments, notional amount and fair value | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.55% | 2.55% | 2.55% | 2.55% | ||
Interest rate swap to 4.125% and 5.125% notes | ||||||
Derivative instruments, notional amount and fair value | ||||||
Unwounded interest rate swaps | $ 1,500 | $ 1,500 | ||||
Proceeds from unwinding of derivatives | $ 55 | |||||
4.125% Notes, due 2020 | ||||||
Derivative instruments, notional amount and fair value | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.125% | 4.125% | 4.125% | |||
5.125% Notes, due 2019 | ||||||
Derivative instruments, notional amount and fair value | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.125% | 5.125% | 5.125% | |||
Designated as hedging instrument | Short-term borrowings | Net investment hedges | ||||||
Derivative instruments, notional amount and fair value | ||||||
Fair Value - Liabilities | $ 454 | $ 454 | 439 | |||
Designated as hedging instrument | Interest rate swaps | Fair value hedges | ||||||
Derivative instruments, notional amount and fair value | ||||||
Notional amount | 5,500 | $ 4,000 | 5,500 | 4,000 | ||
Amount of hedge ineffectiveness recorded in income | 0 | 0 | 0 | |||
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | ||||||
Derivative instruments, notional amount and fair value | ||||||
Notional amount | 2,600 | $ 3,300 | 2,600 | |||
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold | 12 months | |||||
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold | 18 months | |||||
Not designated as hedging instrument | Foreign currency forward exchange contracts | ||||||
Derivative instruments, notional amount and fair value | ||||||
Notional amount | 14,900 | $ 20,100 | 14,900 | $ 14,000 | ||
Dispositions held for sale | AMO | Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | ||||||
Derivative instruments, notional amount and fair value | ||||||
Notional amount | 107 | 107 | ||||
Dispositions held for sale | AMO | Not designated as hedging instrument | Foreign currency forward exchange contracts | ||||||
Derivative instruments, notional amount and fair value | ||||||
Notional amount | $ 1,200 | $ 1,200 |
Financial Instruments, Deriva77
Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Derivative instruments, notional amount and fair value | |||
Fair Value - Assets | $ 138 | $ 284 | |
Fair Value - Liabilities | 298 | 610 | |
Designated as hedging instrument | Short-term borrowings | Net investment hedges | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Liabilities | 454 | $ 439 | |
Designated as hedging instrument | Interest rate swaps | Deferred income taxes and other assets | Fair value hedges | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Assets | 8 | ||
Designated as hedging instrument | Interest rate swaps | Post-employment obligations and other long-term liabilities | Fair value hedges | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Liabilities | 93 | 74 | |
Designated as hedging instrument | Foreign currency forward exchange contracts | Other prepaid expenses and receivables | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Assets | 21 | 99 | |
Designated as hedging instrument | Foreign currency forward exchange contracts | Other accrued liabilities | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Liabilities | 106 | 15 | |
Not designated as hedging instrument | Foreign currency forward exchange contracts | Other prepaid expenses and receivables | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Assets | 117 | 177 | |
Not designated as hedging instrument | Foreign currency forward exchange contracts | Other accrued liabilities | |||
Derivative instruments, notional amount and fair value | |||
Fair Value - Liabilities | $ 99 | $ 67 |
Financial Instruments, Deriva78
Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Interest rate swaps | Fair value hedges | Designated as hedging instrument | Interest expense | |||
Gain (loss) on derivatives | |||
Income (expense) and Gain (loss) Reclassified into Income | $ (24) | $ (127) | $ 15 |
Foreign currency forward exchange contracts | Not designated as hedging instrument | Net foreign exchange loss (gain) | |||
Gain (loss) on derivatives | |||
Income (expense) and Gain (loss) Reclassified into Income | (64) | 8 | (77) |
Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | |||
Gain (loss) on derivatives | |||
Gain (loss) Recognized in Other Comprehensive Income (loss) | (226) | 49 | 91 |
Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | Cost of products sold | |||
Gain (loss) on derivatives | |||
Income (expense) and Gain (loss) Reclassified into Income | (48) | 48 | 124 |
Debt | Net investment hedges | Designated as hedging instrument | |||
Gain (loss) on derivatives | |||
Gain (loss) Recognized in Other Comprehensive Income (loss) | $ (25) | $ (15) | $ 6 |
Financial Instruments, Deriva79
Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 |
Fair value, asset and liability measures | ||
Investments | $ 883 | $ 2,947 |
Foreign currency forward exchange contracts, receivable position | 138 | 284 |
Foreign currency forward exchange contracts, (payable) position | (298) | (610) |
Equity securities | ||
Fair value, asset and liability measures | ||
Investments | 797 | 2,906 |
Carrying Value | ||
Fair value, asset and liability measures | ||
Total long-term debt | (27,718) | (20,684) |
Foreign currency forward exchange contracts, receivable position | 138 | 276 |
Foreign currency forward exchange contracts, (payable) position | (205) | (82) |
Interest rate hedge contracts, receivable position | 8 | |
Interest rate hedge contract, (payable) position | (93) | (74) |
Carrying Value | Equity securities | ||
Fair value, asset and liability measures | ||
Investments | 797 | 2,906 |
Carrying Value | Other | ||
Fair value, asset and liability measures | ||
Investments | 86 | 41 |
Fair Value | ||
Fair value, asset and liability measures | ||
Total long-term debt | (29,018) | (21,147) |
Foreign currency forward exchange contracts, receivable position | 138 | 276 |
Foreign currency forward exchange contracts, (payable) position | (205) | (82) |
Interest rate hedge contracts, receivable position | 8 | |
Interest rate hedge contract, (payable) position | (93) | (74) |
Fair Value | Equity securities | ||
Fair value, asset and liability measures | ||
Investments | 797 | 2,906 |
Fair Value | Other | ||
Fair value, asset and liability measures | ||
Investments | $ 86 | $ 42 |
Financial Instruments, Deriva80
Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - USD ($) shares in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended | ||
Apr. 30, 2015 | Dec. 31, 2017 | Dec. 31, 2015 | Dec. 31, 2016 | |
Fair value, asset and liability measures | ||||
Fair Value - Assets | $ 138 | $ 284 | ||
Fair Value - Liabilities | 298 | 610 | ||
Long-term Investments | 883 | 2,947 | ||
Available-for-sale equity securities in an unrealized loss position | ||||
Proceeds from the sale of Mylan N.V. shares | 2,704 | $ 2,290 | ||
Maximum | ||||
Fair value, asset and liability measures | ||||
Contingent consideration related to business combinations | 525 | |||
Recurring | ||||
Fair value, asset and liability measures | ||||
Trading Securities, Equity | 374 | 2,676 | ||
Interest rate swap derivative financial instruments, assets | 8 | |||
Total Assets | 512 | 2,960 | ||
Fair value of hedged long-term debt | 3,898 | 5,413 | ||
Interest rate swap financial instruments, liabilities | 93 | 74 | ||
Contingent consideration related to business combinations | 120 | 136 | ||
Total Liabilities | 4,316 | 5,705 | ||
Recurring | Foreign currency exchange contracts | ||||
Fair value, asset and liability measures | ||||
Fair Value - Assets | 138 | 276 | ||
Fair Value - Liabilities | 205 | 82 | ||
Recurring | Quoted Prices in Active Markets | ||||
Fair value, asset and liability measures | ||||
Trading Securities, Equity | 374 | 2,676 | ||
Total Assets | 374 | 2,676 | ||
Recurring | Significant Other Observable Inputs | ||||
Fair value, asset and liability measures | ||||
Interest rate swap derivative financial instruments, assets | 8 | |||
Total Assets | 138 | 284 | ||
Fair value of hedged long-term debt | 3,898 | 5,413 | ||
Interest rate swap financial instruments, liabilities | 93 | 74 | ||
Total Liabilities | 4,196 | 5,569 | ||
Recurring | Significant Other Observable Inputs | Foreign currency exchange contracts | ||||
Fair value, asset and liability measures | ||||
Fair Value - Assets | 138 | 276 | ||
Fair Value - Liabilities | 205 | 82 | ||
Recurring | Significant Unobservable Inputs | ||||
Fair value, asset and liability measures | ||||
Contingent consideration related to business combinations | 120 | 136 | ||
Total Liabilities | 120 | 136 | ||
Equity securities | ||||
Fair value, asset and liability measures | ||||
Long-term Investments | $ 797 | $ 2,906 | ||
Equity securities | Mylan N. V. (Investee) | ||||
Fair value, asset and liability measures | ||||
Number of shares in investment sold | 40,250 | 69,750 | ||
Available-for-sale equity securities in an unrealized loss position | ||||
Proceeds from the sale of Mylan N.V. shares | $ 2,290 | $ 2,704 |
Litigation and Environmental 81
Litigation and Environmental Matters (Details) $ in Millions | Dec. 31, 2017USD ($) |
Loss Contingencies | |
Maximum expected cleanup exposure for individual site | $ 4 |
Maximum expected cleanup exposure in aggregate | 10 |
Other legal proceedings and environmental exposures | |
Loss Contingencies | |
Recorded reserve balance for legal proceedings and exposures | 135 |
Other legal proceedings and environmental exposures | Minimum | |
Loss Contingencies | |
Other legal proceedings or environmental exposure | 115 |
Other legal proceedings and environmental exposures | Maximum | |
Loss Contingencies | |
Other legal proceedings or environmental exposure | $ 160 |
Post-Employment Benefits - Bene
Post-Employment Benefits - Benefit Obligation (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Plan assets at fair value: | |||
Plan assets at fair value, balance at the beginning of the period | $ 7,958 | ||
Plan assets at fair value, balance at the end of the period | 9,717 | $ 7,958 | |
Projected benefit obligations greater than plan assets | |||
Long-term liabilities | (2,169) | (2,154) | |
Amounts Recognized in Accumulated Other Comprehensive Income (loss): | |||
Projected benefit obligations | 3,000 | 2,500 | |
Accumulated benefit obligations | 8,900 | 7,400 | |
The aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets | |||
Accumulated benefit obligation | 1,664 | 1,485 | |
Projected benefit obligation | 1,892 | 1,697 | |
Fair value of plan assets | 696 | 653 | |
Defined Benefit Plans | |||
Projected benefit obligations: | |||
Projected benefit obligations, balance at the beginning of the period | 8,517 | 7,820 | |
Service cost - benefits earned during the year | 283 | 263 | $ 307 |
Interest cost on projected benefit obligations | 287 | 288 | 314 |
(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs | 752 | 645 | |
Benefits paid | (276) | (242) | |
Other, including foreign currency translation | 390 | (257) | |
Projected benefit obligations, balance at the end of the period | 9,953 | 8,517 | 7,820 |
Plan assets at fair value: | |||
Plan assets at fair value, balance at the beginning of the period | 7,542 | 6,772 | |
Actual return on plans' assets | 1,107 | 631 | |
Company contributions | 645 | 582 | |
Benefits paid | (276) | (242) | |
Other, including foreign currency translation | 280 | (201) | |
Plan assets at fair value, balance at the end of the period | 9,298 | 7,542 | 6,772 |
Projected benefit obligations greater than plan assets | |||
Projected benefit obligations greater than plan assets, December 31 | (655) | (975) | |
Long-term assets | 563 | 340 | |
Short-term liabilities | (21) | (18) | |
Long-term liabilities | (1,197) | (1,297) | |
Net liability | (655) | (975) | |
Amounts Recognized in Accumulated Other Comprehensive Income (loss): | |||
Actuarial losses, net | 3,466 | 3,301 | |
Prior service cost (credits) | (9) | ||
Total | 3,457 | 3,301 | |
Medical and Dental Plans | |||
Projected benefit obligations: | |||
Projected benefit obligations, balance at the beginning of the period | 1,274 | 1,262 | |
Service cost - benefits earned during the year | 25 | 26 | 33 |
Interest cost on projected benefit obligations | 45 | 43 | 52 |
(Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs | 149 | 13 | |
Benefits paid | (80) | (71) | |
Other, including foreign currency translation | (20) | 1 | |
Projected benefit obligations, balance at the end of the period | 1,393 | 1,274 | 1,262 |
Plan assets at fair value: | |||
Plan assets at fair value, balance at the beginning of the period | 416 | 441 | |
Actual return on plans' assets | 65 | 28 | |
Company contributions | 12 | 10 | |
Benefits paid | (74) | (63) | |
Plan assets at fair value, balance at the end of the period | 419 | 416 | $ 441 |
Projected benefit obligations greater than plan assets | |||
Projected benefit obligations greater than plan assets, December 31 | (974) | (858) | |
Short-term liabilities | (2) | (1) | |
Long-term liabilities | (972) | (857) | |
Net liability | (974) | (858) | |
Amounts Recognized in Accumulated Other Comprehensive Income (loss): | |||
Actuarial losses, net | 456 | 373 | |
Prior service cost (credits) | (208) | (254) | |
Total | $ 248 | $ 119 |
Post-Employment Benefits - Expe
Post-Employment Benefits - Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Defined Benefit Plans | |||
Defined benefit plan net periodic benefit cost | |||
Service cost - benefits earned during the year | $ 283 | $ 263 | $ 307 |
Interest cost on projected benefit obligations | 287 | 288 | 314 |
Expected return on plans' assets | (613) | (565) | (511) |
Amortization of actuarial losses | 163 | 129 | 184 |
Amortization of prior service cost (credits) | 1 | 1 | |
Net cost | 121 | 115 | 295 |
Net actuarial losses (gains), net of any prior service credits | (247) | (571) | 37 |
Pretax amount included in accumulated other comprehensive income (loss), expected to be recognized in the net period benefit cost in 2017 | |||
Pretax amount of actuarial losses expected to recognized in the net periodic benefit cost in 2018 | 213 | ||
Pretax amount of prior service cost (credits) expected to recognized in the net periodic benefit cost in 2018 | 1 | ||
Defined Benefit Plans | Discontinued operations | |||
Defined benefit plan net periodic benefit cost | |||
Net cost | 3 | ||
Defined Benefit Plans | Continuing operations | |||
Defined benefit plan net periodic benefit cost | |||
Net cost | 121 | 115 | 292 |
Medical and Dental Plans | |||
Defined benefit plan net periodic benefit cost | |||
Service cost - benefits earned during the year | 25 | 26 | 33 |
Interest cost on projected benefit obligations | 45 | 43 | 52 |
Expected return on plans' assets | (33) | (35) | (39) |
Amortization of actuarial losses | 23 | 16 | 23 |
Amortization of prior service cost (credits) | (45) | (45) | (48) |
Net cost | 15 | 5 | 21 |
Net actuarial losses (gains), net of any prior service credits | (97) | (20) | 116 |
Pretax amount included in accumulated other comprehensive income (loss), expected to be recognized in the net period benefit cost in 2017 | |||
Pretax amount of actuarial losses expected to recognized in the net periodic benefit cost in 2018 | 31 | ||
Pretax amount of prior service cost (credits) expected to recognized in the net periodic benefit cost in 2018 | 45 | ||
Medical and Dental Plans | Continuing operations | |||
Defined benefit plan net periodic benefit cost | |||
Net cost | 15 | $ 5 | $ 21 |
AMO | |||
Defined benefit plan net periodic benefit cost | |||
Curtailment gain related to sale of AMO | $ 10 |
Post-Employment Benefits - Assu
Post-Employment Benefits - Assumptions (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
A one percentage point increase / (decrease) in the assumed health care cost | |||
Increase in accumulated post employment benefit obligations due to a one percentage point increase in the assumed health care cost | $ 179 | ||
Decrease in accumulated post employment benefit obligations due to a one percentage point decrease in the assumed health care cost | (150) | ||
Increase in the total of service and interest cost components of net post employment health care cost due to a one percentage point increase in the assumed health care cost | 11 | ||
Decrease in the total of service and interest cost components of net post employment health care cost due to a one percentage point decrease in the assumed health care cost | $ (9) | ||
Defined benefit plans and medical and dental plans | |||
Weighted average assumptions used to determine benefit obligations | |||
Discount rate (as a percent) | 3.40% | 3.90% | 4.30% |
Expected aggregate average long-term change in compensation (as a percent) | 4.40% | 4.30% | 4.40% |
Weighted average assumptions used to determine the net cost | |||
Discount rate (as a percent) | 3.90% | 4.30% | 3.90% |
Expected return on plan assets (as a percent) | 7.60% | 7.60% | 7.40% |
Expected aggregate average long-term change in compensation (as a percent) | 4.30% | 4.30% | 4.30% |
Medical and Dental Plans | |||
Assumed health care cost trend rates | |||
Health care cost trend rate assumed for the next year (as a percent) | 9.00% | 8.00% | 8.00% |
Rate that the cost trend rate gradually declines to (as a percent) | 5.00% | 5.00% | 5.00% |
Year that rate reaches the assumed ultimate rate | 2,027 | 2,027 | 2,028 |
Post-Employment Benefits - Asse
Post-Employment Benefits - Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | $ 9,717 | $ 7,958 |
Unfunded commitments | 489 | 337 |
U.S. large cap | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 2,506 | 1,889 |
U.S. mid and small cap | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 670 | 549 |
International | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 1,937 | 1,345 |
U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 510 | 437 |
Corporate debt instruments | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 930 | 813 |
Non-U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 625 | 514 |
Other | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 216 | 183 |
Absolute return funds | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 1,814 | 1,891 |
Commodities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 60 | 84 |
Cash and Cash Equivalents | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 178 | 100 |
Other. | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 271 | 153 |
Quoted Prices in Active Markets | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 2,878 | 2,297 |
Quoted Prices in Active Markets | U.S. large cap | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 1,600 | 1,284 |
Quoted Prices in Active Markets | U.S. mid and small cap | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 243 | 183 |
Quoted Prices in Active Markets | International | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 448 | 356 |
Quoted Prices in Active Markets | U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 11 | 5 |
Quoted Prices in Active Markets | Corporate debt instruments | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 107 | 100 |
Quoted Prices in Active Markets | Non-U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 222 | 175 |
Quoted Prices in Active Markets | Other | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 93 | 80 |
Quoted Prices in Active Markets | Absolute return funds | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 135 | 106 |
Quoted Prices in Active Markets | Cash and Cash Equivalents | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 12 | 8 |
Quoted Prices in Active Markets | Other. | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 7 | |
Significant Other Observable Inputs | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 724 | 626 |
Significant Other Observable Inputs | U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 286 | 258 |
Significant Other Observable Inputs | Corporate debt instruments | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 411 | 348 |
Significant Other Observable Inputs | Other | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 27 | 20 |
Significant Unobservable Inputs | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 4 | 12 |
Significant Unobservable Inputs | Commodities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 4 | 12 |
Measured at NAV | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 6,111 | 5,023 |
Measured at NAV | U.S. large cap | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 906 | 605 |
Measured at NAV | U.S. mid and small cap | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 427 | 366 |
Measured at NAV | International | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 1,489 | 989 |
Measured at NAV | U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 213 | 174 |
Measured at NAV | Corporate debt instruments | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 412 | 365 |
Measured at NAV | Non-U.S. government securities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 403 | 339 |
Measured at NAV | Other | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 96 | 83 |
Measured at NAV | Absolute return funds | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 1,679 | 1,785 |
Measured at NAV | Commodities | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 56 | 72 |
Measured at NAV | Cash and Cash Equivalents | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | 166 | 92 |
Measured at NAV | Other. | ||
Defined benefit plans disclosures | ||
Defined benefit plans' assets at fair value | $ 264 | $ 153 |
Equities | Minimum | ||
Defined benefit plans disclosures | ||
Redemption notice period | 7 days | |
Equities | Maximum | ||
Defined benefit plans disclosures | ||
Redemption notice period | 30 days | |
Fixed Income Securities | ||
Defined benefit plans disclosures | ||
Maximum amount of fund with redemption limit to 25% | $ 100 | |
Maximum redemption fund percentage | 25.00% | |
Fixed Income Securities | Minimum | ||
Defined benefit plans disclosures | ||
Redemption notice period | 2 days | |
Fixed Income Securities | Maximum | ||
Defined benefit plans disclosures | ||
Redemption notice period | 14 days | |
Absolute return funds and commodity | Minimum | ||
Defined benefit plans disclosures | ||
Redemption notice period | 5 days | |
Absolute return funds and commodity | Maximum | ||
Defined benefit plans disclosures | ||
Redemption notice period | 45 days |
Post-Employment Benefits - Fund
Post-Employment Benefits - Funding and Payments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Total benefit payments expected to be paid to participants | |||
Contribution to Abbott Stock Retirement Plan, defined contribution plan | $ 79 | $ 83 | $ 81 |
Defined Benefit Plans | |||
Defined benefit plans disclosures | |||
Company contributions | 645 | 582 | |
Defined benefit plan, expected contributions in future | 114 | ||
Total benefit payments expected to be paid to participants | |||
2,018 | 278 | ||
2,019 | 289 | ||
2,020 | 307 | ||
2,021 | 324 | ||
2,022 | 344 | ||
2023 to 2027 | 2,032 | ||
Medical and Dental Plans | |||
Defined benefit plans disclosures | |||
Company contributions | 12 | $ 10 | |
Total benefit payments expected to be paid to participants | |||
2,018 | 68 | ||
2,019 | 71 | ||
2,020 | 74 | ||
2,021 | 77 | ||
2,022 | 79 | ||
2023 to 2027 | $ 421 |
Taxes on Earnings from Contin87
Taxes on Earnings from Continuing Operations - US Tax Reform (Details) - USD ($) $ in Millions | Jan. 01, 2018 | Dec. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Taxes on Earnings | |||||
Federal corporate tax rate (in percent) | 21.00% | 35.00% | 35.00% | 35.00% | |
Net tax expense by impact of TCJA | $ 1,460 | ||||
Income tax charge relating to transition tax | 2,890 | ||||
Income tax benefit on remeasurement of deferred tax assets and liabilities | 1,420 | ||||
Income tax benefit by other impacts of TCJA | $ 10 | ||||
Favorable resolution of various tax positions and other unusual provision items | $ (225) | ||||
AMO | Disposal Group, Disposed of by Sale, Not Discontinued Operations | |||||
Taxes on Earnings | |||||
Tax expense (benefit) on gain or loss on sale of business | $ 435 | ||||
Mylan N. V. (Investee) | Disposal Group, Disposed of by Sale, Not Discontinued Operations | |||||
Taxes on Earnings | |||||
Tax expense (benefit) on gain or loss on sale of business | $ 71 |
Taxes on Earnings from Contin88
Taxes on Earnings from Continuing Operations - Earnings and Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Earnings From Continuing Operations Before Taxes: | |||
Domestic | $ 308 | $ 306 | $ 789 |
Foreign | 1,923 | 1,107 | 2,394 |
Earnings from Continuing Operations Before Taxes | 2,231 | 1,413 | 3,183 |
Current: | |||
Domestic, current tax | 2,260 | 71 | 64 |
Foreign, current tax | 508 | 406 | 220 |
Total current taxes | 2,768 | 477 | 284 |
Deferred: | |||
Domestic, deferred tax | (679) | (147) | 313 |
Foreign, deferred tax | (211) | 20 | (20) |
Total deferred taxes | (890) | (127) | 293 |
Total | $ 1,878 | $ 350 | $ 577 |
Taxes on Earnings from Contin89
Taxes on Earnings from Continuing Operations - Tax Rate Reconciliation (Details) | Jan. 01, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Differences between the effective income tax rate and the U.S. statutory tax rate: | ||||
Statutory tax rate on earnings from continuing operations (as a percent) | 21.00% | 35.00% | 35.00% | 35.00% |
Impact of foreign operations (as a percent) | (16.30%) | (17.80%) | (18.20%) | |
Impact of TCJA (as a percent) | 65.50% | |||
Excess tax benefits related to stock compensation (as a percent) | (5.40%) | |||
Research tax credit (as a percent) | (1.90%) | (1.80%) | (0.60%) | |
Resolution of certain tax positions pertaining to prior years (as a percent) | (16.10%) | |||
Mylan share adjustment (as a percent) | 25.50% | |||
State taxes, net of federal benefit (as a percent) | 0.50% | (1.30%) | 0.30% | |
Federal tax cost on sale of Mylan N.V. shares (as a percent) | 3.40% | 2.20% | ||
All other, net (as a percent) | 3.40% | 1.30% | (0.60%) | |
Effective tax rate on earnings from continuing operations (as a percent) | 84.20% | 24.80% | 18.10% |
Taxes on Earnings from Contin90
Taxes on Earnings from Continuing Operations - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2017 | Dec. 31, 2016 |
Deferred tax assets: | ||
Compensation and employee benefits | $ 881 | $ 1,061 |
Other, primarily reserves not currently deductible, and NOL's and credit carryforwards | 2,795 | 2,384 |
Trade receivable reserves | 185 | 207 |
Inventory reserves | 152 | 157 |
Deferred intercompany profit | 249 | 231 |
State income taxes | 62 | 164 |
Total deferred tax assets before valuation allowance | 4,324 | 4,204 |
Valuation allowance | (1,355) | (189) |
Total deferred tax assets | 2,969 | 4,015 |
Deferred tax liabilities: | ||
Depreciation | (200) | (152) |
Unremitted earnings of foreign subsidiaries | (175) | |
Other, primarily the excess of book basis over tax basis of intangible assets | (3,385) | (2,018) |
Total deferred tax liabilities | 3,585 | 2,345 |
Total net deferred tax assets | $ 1,670 | |
Total net deferred tax liabilities | $ (616) |
Taxes on Earnings from Contin91
Taxes on Earnings from Continuing Operations - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Reconciliation of Unrecognized Tax Benefits | ||
Balance at the beginning of the period | $ 972 | $ 1,438 |
Increase in tax positions due to acquisitions | 479 | |
Increase due to current year tax positions | 187 | 145 |
Increase due to prior year tax positions | 76 | 101 |
Decrease due to prior year tax positions | (176) | (703) |
Settlements | (57) | (9) |
Lapse of statute | (41) | |
Balance at the end of the period | 1,440 | $ 972 |
Unrecognized tax benefits that would impact effective tax rate | 1,360 | |
Minimum | ||
Reconciliation of Unrecognized Tax Benefits | ||
Decrease reasonably possible in gross unrecognized tax benefits | 150 | |
Maximum | ||
Reconciliation of Unrecognized Tax Benefits | ||
Decrease reasonably possible in gross unrecognized tax benefits | $ 300 |
Segment and Geographical Area I
Segment and Geographical Area Information - Sales and Earnings (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | $ 7,589 | $ 6,829 | $ 6,637 | $ 6,335 | $ 5,333 | $ 5,302 | $ 5,333 | $ 4,885 | $ 27,390 | $ 20,853 | $ 20,405 |
Operating Earnings | 1,726 | 3,185 | 2,867 | ||||||||
Other | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 1,651 | 2,386 | 2,272 | ||||||||
Total Reportable Segments | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 25,739 | 18,467 | 18,133 | ||||||||
Operating Earnings | 6,625 | 4,614 | 4,631 | ||||||||
Total Reportable Segments | Established Pharmaceutical Products | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 4,287 | 3,859 | 3,720 | ||||||||
Operating Earnings | 848 | 723 | 658 | ||||||||
Total Reportable Segments | Nutritional Products | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 6,925 | 6,899 | 6,975 | ||||||||
Operating Earnings | 1,589 | 1,660 | 1,741 | ||||||||
Total Reportable Segments | Diagnostic Products | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 5,616 | 4,813 | 4,646 | ||||||||
Operating Earnings | 1,468 | 1,194 | 1,171 | ||||||||
Total Reportable Segments | Cardiovascular and Neuromodulation Products | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 8,911 | 2,896 | 2,792 | ||||||||
Operating Earnings | $ 2,720 | $ 1,037 | $ 1,061 |
Segment and Geographical Area93
Segment and Geographical Area Information - Reconciliation (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Segment and Geographical Area Information | |||
Operating Earnings | $ 1,726 | $ 3,185 | $ 2,867 |
Amortization of intangible assets | (1,975) | (550) | (601) |
Earnings from Continuing Operations Before Taxes | 2,231 | 1,413 | 3,183 |
Mylan N.V. equity investment adjustment | 947 | ||
Foreign currency exchange loss on remeasurement | 480 | ||
Gain on sale of Mylan shares | 45 | 207 | |
Venezuela | |||
Segment and Geographical Area Information | |||
Foreign currency exchange loss on remeasurement | 480 | ||
Total Reportable Segments | |||
Segment and Geographical Area Information | |||
Operating Earnings | 6,625 | 4,614 | 4,631 |
Corporate functions | |||
Segment and Geographical Area Information | |||
Corporate functions and benefit plans costs | (506) | (411) | (416) |
Reconciling items | |||
Segment and Geographical Area Information | |||
Non-reportable segments | 306 | 304 | 268 |
Net interest expense | (780) | (332) | (58) |
Share-based compensation | (406) | (310) | (291) |
Amortization of intangible assets | (1,975) | (550) | (601) |
Other, net | (1,033) | (1,902) | (350) |
Mylan N.V. equity investment adjustment | 947 | ||
Separation related costs and cost reduction initiatives and integration | $ 384 | 167 | 310 |
Gain on sale of Mylan shares | $ 207 | ||
Reconciling items | Venezuela | |||
Segment and Geographical Area Information | |||
Foreign currency exchange loss on remeasurement | $ 480 |
Segment and Geographical Area94
Segment and Geographical Area Information - Depreciation and Assets (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Segment and Geographical Area Information | |||
Depreciation | $ 1,046 | $ 803 | $ 871 |
Additions to Property, Plant and Equipment | 1,135 | 1,121 | 1,110 |
Total Assets | 76,250 | 52,666 | 41,247 |
Segment assets: | |||
Total Assets | 76,250 | 52,666 | 41,247 |
Other | |||
Segment and Geographical Area Information | |||
Depreciation | 194 | 236 | 247 |
Additions to Property, Plant and Equipment | 227 | 370 | 508 |
Non-reportable segment | |||
Segment and Geographical Area Information | |||
Total Assets | 740 | 1,280 | 1,267 |
Segment assets: | |||
Total Assets | 740 | 1,280 | 1,267 |
Total Reportable Segments | |||
Segment and Geographical Area Information | |||
Depreciation | 852 | 567 | 624 |
Additions to Property, Plant and Equipment | 908 | 751 | 602 |
Total Assets | 15,188 | 10,045 | 9,777 |
Segment assets: | |||
Total Assets | 15,188 | 10,045 | 9,777 |
Total Reportable Segments | Established Pharmaceutical Products | |||
Segment and Geographical Area Information | |||
Depreciation | 90 | 71 | 83 |
Additions to Property, Plant and Equipment | 181 | 150 | 112 |
Total Assets | 2,728 | 2,486 | 2,210 |
Segment assets: | |||
Total Assets | 2,728 | 2,486 | 2,210 |
Total Reportable Segments | Nutritional Products | |||
Segment and Geographical Area Information | |||
Depreciation | 164 | 160 | 157 |
Additions to Property, Plant and Equipment | 147 | 199 | 139 |
Total Assets | 3,160 | 3,189 | 3,187 |
Segment assets: | |||
Total Assets | 3,160 | 3,189 | 3,187 |
Total Reportable Segments | Diagnostic Products | |||
Segment and Geographical Area Information | |||
Depreciation | 300 | 267 | 310 |
Additions to Property, Plant and Equipment | 374 | 379 | 319 |
Total Assets | 4,226 | 2,945 | 2,844 |
Segment assets: | |||
Total Assets | 4,226 | 2,945 | 2,844 |
Total Reportable Segments | Cardiovascular and Neuromodulation Products | |||
Segment and Geographical Area Information | |||
Depreciation | 298 | 69 | 74 |
Additions to Property, Plant and Equipment | 206 | 23 | 32 |
Total Assets | 5,074 | 1,425 | 1,536 |
Segment assets: | |||
Total Assets | 5,074 | 1,425 | 1,536 |
Reconciling items | |||
Segment assets: | |||
Cash and investments | 10,493 | 21,722 | 10,166 |
Goodwill and intangible assets | 45,493 | 12,222 | 15,200 |
All other | $ 4,336 | $ 7,397 | $ 4,837 |
Segment and Geographic Area I95
Segment and Geographic Area Information - Geographic Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | $ 7,589 | $ 6,829 | $ 6,637 | $ 6,335 | $ 5,333 | $ 5,302 | $ 5,333 | $ 4,885 | $ 27,390 | $ 20,853 | $ 20,405 |
Long-lived assets | 8,900 | 6,600 | 8,900 | 6,600 | |||||||
United States | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 9,673 | 6,486 | 6,270 | ||||||||
Long-lived assets | $ 4,500 | $ 3,100 | 4,500 | 3,100 | |||||||
China | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 2,146 | 1,728 | 1,796 | ||||||||
Germany | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 1,366 | 1,044 | 1,004 | ||||||||
Japan | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 1,255 | 924 | 895 | ||||||||
India | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 1,237 | 1,114 | 1,053 | ||||||||
The Netherlands | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 929 | 830 | 855 | ||||||||
Switzerland | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 841 | 766 | 784 | ||||||||
Russia | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 664 | 554 | 483 | ||||||||
France | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 628 | 352 | 375 | ||||||||
Brazil | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 541 | 410 | 381 | ||||||||
Italy | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 507 | 365 | 383 | ||||||||
United Kingdom | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 498 | 377 | 430 | ||||||||
Colombia | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 494 | 424 | 388 | ||||||||
Canada | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 443 | 408 | 428 | ||||||||
Vietnam | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | 427 | 434 | 331 | ||||||||
All Other Countries | |||||||||||
Segment and Geographical Area Information | |||||||||||
Net Sales to External Customers | $ 5,741 | $ 4,637 | $ 4,549 |
Quarterly Results (Unaudited)96
Quarterly Results (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Net Sales | $ 7,589 | $ 6,829 | $ 6,637 | $ 6,335 | $ 5,333 | $ 5,302 | $ 5,333 | $ 4,885 | $ 27,390 | $ 20,853 | $ 20,405 |
Gross Profit | 3,766 | 3,471 | 3,072 | 2,769 | 2,900 | 2,877 | 2,901 | 2,601 | |||
Earnings (Loss) from Continuing Operations | $ (864) | $ 561 | $ 270 | $ 386 | $ 765 | $ (357) | $ 599 | $ 56 | $ 353 | $ 1,063 | $ 2,606 |
Basic Earnings (Loss) per Common Share | $ (0.50) | $ 0.32 | $ 0.15 | $ 0.22 | $ 0.51 | $ (0.24) | $ 0.40 | $ 0.04 | $ 0.20 | $ 0.71 | $ 1.73 |
Diluted Earnings (Loss) per Common Share | $ (0.50) | $ 0.32 | $ 0.15 | $ 0.22 | $ 0.51 | $ (0.24) | $ 0.40 | $ 0.04 | $ 0.20 | $ 0.71 | $ 1.72 |
Net Earnings (Loss) | $ (828) | $ 603 | $ 283 | $ 419 | $ 798 | $ (329) | $ 615 | $ 316 | $ 477 | $ 1,400 | $ 4,423 |
Basic Earnings (Loss) Per Common Share (in dollars per share) | $ (0.48) | $ 0.34 | $ 0.16 | $ 0.24 | $ 0.54 | $ (0.22) | $ 0.41 | $ 0.21 | $ 0.27 | $ 0.94 | $ 2.94 |
Diluted Earnings (Loss) Per Common Share (in dollars per share) | (0.48) | 0.34 | 0.16 | 0.24 | 0.53 | (0.22) | 0.41 | 0.21 | 0.27 | 0.94 | $ 2.92 |
Maximum | |||||||||||
Market Price Per Share | 57.77 | 54.80 | 49.59 | 45.84 | 43.78 | 45.79 | 44.58 | 44.05 | 57.77 | 43.78 | |
Minimum | |||||||||||
Market Price Per Share | $ 53.20 | $ 47.83 | $ 42.31 | $ 38.34 | $ 37.38 | $ 39.16 | $ 36.76 | $ 36 | $ 53.20 | $ 37.38 |